Effector-deficient anti-cd32a  antibodies

ABSTRACT

Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.

SEQUENCE LISTING

The instant application contains a Sequence Listing, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 20, 2014, is named 01119-0008-00US_SL.txt and is 111,245 bytes in size.

FIELD

Methods and compositions for treating and preventing diseases and disorders mediated by CD32a are provided.

BACKGROUND

The effector, or Fc, regions of antibodies bind to various receptors on many different cell types. One such receptor is the CD32a IgG receptor (also known as FcgammaRIIa). It has been reported that human platelets and other human cells, such as basophils, eosinophils, monocytes, neutrophils, dendritic cells, macrophages, and mast cells, display cell surface CD32a receptors (Hogarth P M et al. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond (March 2012) Nat Rev Drug Discov 11:311; PubMed ID: 22460124; Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models (June 2012) Blood 119:5640; PubMed ID: 22535666). Activation of CD32a by Fc regions of IgG antibodies (regardless of antigen specificity) results in a number of in vivo reactions, many of which have negative consequences for the human host. For example, IgG activation of CD32a can contribute to fatality in heparin-induced thrombocytopenia (HIT; see Boon D M et al. Heparin-induced thrombocytopenia and thrombosis: a potential fatal complication in a routine treatment (March 1995) Neth J Med 46:146; PubMed ID: 7731489; and Warkentin T E et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia (December 1994) Blood 84:3691; PubMed ID: 7949124). It has also been reported that IgG-mediated activation of CD32a on neutrophils, monocytes, and macrophages promotes airway inflammation, allergic reactions, and anaphylaxis. See, e.g. Jönsson F. et al. Human Fc-gamma-RIIA induces anaphylactic and allergic reactions (2012 Mar. 15) Blood 119:2533-44, PubMed ID: 22138510. Activation of CD32a by IgG-Fc can also contribute to thrombosis in HIT (see, e.g. Arepally G et al. Fc gamma RIIA HSR 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis (January 1997) Blood 89:370; PubMed ID: 9002937; Newman P M et al. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation (July 2000) Blood 96:182; PubMed ID: 10891449; Jaffray B et al. Fatal venous thrombosis after heparin therapy (March 1991) Lancet 337:561; PubMed ID: 1671929).

In a 2012 report by Jönsson et al., the authors reported that blocking the CD32a receptor protected mice from local and systemic anaphylaxis, and concluded that “[t]argeting Fc[gamma]RIIA with specific blocking molecules in inflammation and autoimmune/allergic reactions in humans might lead to similar inhibition as we reported recently for mouse Fc[gamma]RIIIA in a murine model of rheumatoid arthritis.” Id. at 2542. Jönsson continued that “[b]locking Fc[gamma]RIIA using divalent ligands (eg, mAb IV.3) to prevent allergic and autoimmune disease in humans, however, should not be envisioned, as we report here that high-doses of mAb IV.3 induced rather than prevented anaphylaxis.” Id. at 2542 (emphasis added). Thus, while blockade of CD32a was a desired goal for treating inflammatory, autoimmune and allergic disorders, those of skill in the art did not envision blockade with CD32a antibodies due to their known negative side effects upon in vivo administration. The inventors have now solved this problem by providing novel CD32a antibodies that do not elicit negative side effects such as anaphylaxis.

In addition to diseases and disorders mediated by activation of CD32a, a number of diseases and disorders are mediated by CD32a interactions with the Fc regions of immobilized IgG, which do not directly activate CD32a. “Immobilized IgG” refers to antibody molecules that are bound to, or precipitated on, a surface and thus have restricted mobility (i.e., are “immobilized”). Cells having immobilized IgG may alternatively be described as “IgG-coated” cells. CD32a is known to interact only weakly with the Fc region of single IgG molecules, whether soluble (Hogarth P M et al. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond (March 2012) Nat Rev Drug Discov 11:311; PubMed ID: 22460124) or immobilized (Wines B D et al. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A (May 2000) J Immunol 164:5313; PubMed ID: 10799893). Thus, antibodies incapable of directly activating CD32a nevertheless caused CD32a-mediated diseases and disorders such as thrombocytopenia when such antibodies were immobilized on the platelet surface (McKenie et al. The role of the human Fc receptor FcgammaRIIA in the immune clearance of platelets: a transgenic mouse model (April 1999) J Immunol 162:4311; PubMed ID: 10201963).

IgG-coated platelets (or other cells) are actively cleared from the circulating blood. For example, it is well known that in immune thrombocytopenic purpura (ITP), human patients with circulating anti-platelet antibodies (typically IgG) experience platelet clearance mediated in large part by the spleen and the liver, where Fc-receptors (including CD32a) on phagocytes bind and retain the IgG-coated platelets. Removal of the spleen (splenectomy) can alleviate this condition. Unlike with HIT, however, thrombosis is not typically associated with the clearance of IgG-coated platelets in ITP; rather, the clinical problem of bleeding is the more prominent concern, and improved therapeutic strategies for this problem are needed (Altomare I et al. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data (October 2012) Am J Hematol 87:984; PubMed ID: 22729832).

CD32a is also known to mediate clearance of IgG-coated red blood cells (erythrocytes) in CD32a mediated diseases and disorders such as autoimmune hemolytic anemia (AIHA). Targeting CD32a with blocking mAbs would thus seem to be of great utility in treating AIHA; indeed, this was reported with the anti-CD32 mAb, MDE-8, which was shown to ameliorate IgG antibody-induced anemia in mice having a human CD32a transgene but otherwise lacking classical mouse IgG receptor function—that is, the animals used to test MDE-8 lacked functional mouse IgG receptors of type I (CD64) and type III (CD16), leaving open the question as to how these might affect MDE-8 activity in vivo (van Royen-Kerkhof A et al. A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice (July 2005) Br J Haematol 130:130; PubMed ID: 15982355). MDE-8 has not been developed as a therapeutic antibody. Reasons for the lack of preclinical development of MDE-8 have not been publicly disclosed. However, the inventors have now identified and solved a previously undescribed problem with MDE-8 and other anti-CD32a antibodies, namely by modifying them to reduce binding to IgG Fc-receptors, and so that they no longer mediate clearance via CD32a when immobilized on cells, thereby making clinical development possible.

Compositions that can prevent CD32a-mediated clearance of IgG-coated cells without causing negative side effects are therefore desired. The inventors herein describe such compositions and detail their successful use to treat and prevent CD32a-mediated diseases and disorders.

SUMMARY

In accordance with the description, the inventors have discovered that administration of native anti-CD32a antibodies in vivo causes adverse reactions that include thrombocytopenia, drop in body temperature, and symptoms of shock. The inventors have found that administering effector-deficient anti-CD32a antibodies alleviates these adverse reactions.

Therefore, in one embodiment, the present invention provides a method for preventing adverse reactions caused by administration of anti-CD32a antibodies by administering effector-deficient anti-CD32a antibodies. Similarly, methods for treating CD32a-mediated diseases or disorders comprising administering effector-deficient CD32a antibodies are provided.

In some instances, the CD32a-mediated disease or disorder is thrombocytopenia.

In other embodiments, the CD32a-mediated disease or disorder is a symptom of shock, including anaphylactic shock.

In still further embodiments, the CD32a-mediated disease or disorder is an inflammatory, immune, or autoimmune disease or disorder, including rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, inflammatory bowel disease, osteoarthritis, and systemic lupus erythematous (SLE).

In still further embodiments, the CD32a-mediated disease or disorder is heparin-induced thrombocytopenia (HIT), immune thrombocytopenic purpura (ITP), antiphospholipid syndrome (APS), thrombosis or thrombocytopenia associated with autoimmunity or with certain drugs (e.g., heparin) and antibody therapies (e.g., anti-VEGF, anti-TNFalpha, anti-IgE, or anti-CD40L immunotherapies), transfusion or organ transplantation reactions, viral infection, bacterial infection, allergic asthma, allergic rhinitis, lupus nephritis, antibody-mediated anemia, anaphylaxis, chronic idiopathic urticaria (CIU), or airway inflammation.

The inventors have further discovered that administering effector-competent non-anti-CD32a IgG antibodies can cause adverse reactions, including thrombocytopenia, a drop in body temperature, or symptoms of shock. Administering effector-deficient anti-CD32a antibodies prevents these adverse reactions. Therefore, in one embodiment, the present invention provides a method of administering effector-deficient anti-CD32a antibodies to treat adverse reactions caused by IgG antibodies, including non-CD32a antibodies.

Compounds for use in these methods are provided, including effector-deficient chimeric and humanized AT-10 and IV.3 and effector-deficient human MDE-8 monoclonal IgG antibodies. The effector-deficient antibodies comprise at least a portion of the Fc region, and may be full length or may be truncated.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows core body temperatures as a representative measure of infusion reaction in CD32A mice injected with either native human MDE-8 antibodies (IgG1, IgG2), or two different effector-deficient versions of the same MDE-8 antibodies. These effector-deficient antibodies do not cause infusion reactions.

FIG. 2 shows severe thrombocytopenia following intravenous injection of native human MDE-8 mAbs into CD32A mice and no thrombocytopenia following intravenous injection of two representative effector-deficient human MDE-8 antibodies.

FIG. 3A shows flow cytometric analysis of whole blood from CD32A mice prior to injection of native MDE-8 IgG1 mAbs.

FIG. 3B shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of native MDE-8 IgG1 mAbs.

FIG. 3C shows flow cytometric analysis of whole blood from CD32A mice prior to injection of effector-deficient MDE-8 IgG1 mAbs.

FIG. 3D shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of effector-deficient MDE-8 IgG1 mAbs.

FIG. 3E shows flow cytometric analysis of whole blood from CD32A mice prior to injection of native MDE-8 IgG2 mAbs.

FIG. 3F shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of native MDE-8 IgG2 mAbs.

FIG. 3G shows flow cytometric analysis of whole blood from CD32A mice prior to injection of effector-deficient MDE-8 IgG2 mAbs.

FIG. 3H shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of effector-deficient MDE-8 IgG2 mAbs.

FIG. 4A shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of IgG immune complexes.

FIG. 4B shows flow cytometric analysis of whole blood from effector-deficient MDE-8 IgG1 E269R anti-CD32a mAb pre-treated CD32A mice after intravenous injection of IgG immune complexes.

FIG. 4C shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of IgG immune complexes.

FIG. 4D shows flow cytometric analysis of whole blood from effector-deficient MDE-8 IgG2 N297A anti-CD32a mAb pre-treated CD32A mice after intravenous injection of IgG immune complexes.

FIG. 5A shows severe thrombocytopenia following intravenous injection of IgG immune complexes into CD32A mice (#1) but not following immune complex injection into CD32A mice pretreated with effector-deficient MDE-8 IgG1 E269R anti-CD32a mAb (#'s 2-4).

FIG. 5B shows severe thrombocytopenia following intravenous injection of IgG immune complexes into CD32A mice (#1) but not following immune complex injection into CD32A mice pretreated with effector-deficient MDE-8 IgG2 N297A anti-CD32a mAb (#'s 2-3).

FIG. 6A shows the presence of thrombi in the pulmonary blood vessels of CD32A mice after injection of IgG immune complexes.

FIG. 6B shows no thrombosis in the pulmonary blood vessels following IgG immune complex injection into CD32A mice pretreated with effector-deficient MDE-8 IgG1 E269R anti-CD32a mAbs.

FIG. 6C shows the number of pulmonary thrombi in CD32A mice either treated with vehicle (#1) or with effector-deficient MDE-8 IgG1 E269R anti-CD32a mAbs (#'s 2-4).

FIG. 7A shows the presence of thrombi in the pulmonary blood vessels of CD32A mice after injection of IgG immune complexes.

FIG. 7B shows no thrombosis in the pulmonary blood vessels following IgG immune complex injection into CD32A mice pretreated with effector-deficient MDE-8 IgG2 N297A anti-CD32a mAbs.

FIG. 7C shows the number of pulmonary thrombi in CD32A mice either treated with vehicle (#1) or with effector-deficient MDE-8 IgG2 N297A anti-CD32a mAbs (#'s 2-3).

FIG. 8 shows severe thrombocytopenia following intravenous injection of native chimeric AT-10 human IgG1 mAb into CD32A mice but not following intravenous injection of effector-deficient chimeric AT-10 human IgG1 E269R.

FIG. 9A shows flow cytometric analysis of whole blood from CD32A mice prior to injection of native chimeric AT-10 human IgG1 mAbs.

FIG. 9B shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of native chimeric AT-10 human IgG1 mAbs.

FIG. 9C shows flow cytometric analysis of whole blood from CD32A mice prior to injection of effector-deficient chimeric AT-10 human IgG1 mAbs.

FIG. 9D shows flow cytometric analysis of whole blood from CD32A mice after the injection of effector-deficient chimeric AT-10 human IgG1 mAbs.

FIG. 10 shows severe thrombocytopenia following intravenous injection of IgG immune complexes into CD32A mice (#1) but not following immune complex injection into CD32A mice pretreated with effector-deficient chimeric AT-10 human IgG1 E269R anti-CD32a mAb (#'s 2-3).

FIG. 11A shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of IgG immune complexes.

FIG. 11B shows flow cytometric analysis of whole blood from effector-deficient chimeric AT-10 human IgG1 E269R anti-CD32a mAb pre-treated CD32A mice after intravenous injection of IgG immune complexes.

FIG. 12A shows the presence of thrombi in the pulmonary blood vessels of CD32A mice after injection of IgG immune complexes.

FIG. 12B shows no thrombosis in the pulmonary blood vessels following IgG immune complex injection into CD32A mice pretreated with effector-deficient chimeric AT-10 human IgG1 E269R anti-CD32a mAb.

FIG. 12C shows the number of pulmonary thrombi in CD32A mice either treated with vehicle (#1) or with effector-deficient chimeric AT-10 human IgG1 E269R anti-CD32a mAb (#'s 2-3).

FIG. 13A shows no drop in body temperature of CD32A mice injected with effector-deficient humanized AT-10 IgG1 E269R (here and below, this is “hAT-10” mAb).

FIG. 13B shows flow cytometric analysis of whole blood from CD32A mice before intravenous injection of effector-deficient humanized AT-10 IgG1 E269R

FIG. 13C shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of effector-deficient humanized AT-10 IgG1 E269R.

FIG. 13D shows flow cytometric analysis of whole blood from vehicle pre-treated CD32A mice after intravenous injection of IgG immune complexes.

FIG. 13E shows flow cytometric analysis of whole blood from effector-deficient humanized AT-10 IgG1 E269R anti-CD32a mAb pre-treated CD32A mice after intravenous injection of IgG immune complexes.

FIG. 13F shows the number of pulmonary thrombi in CD32A mice either treated with vehicle or with effector-deficient humanized AT-10 IgG1 E269R anti-CD32a mAb.

FIG. 13G shows the presence of occlusive thrombi in the pulmonary blood vessels of CD32A mice after injection of IgG immune complexes.

FIG. 13H shows no thrombosis in the pulmonary blood vessels following IgG immune complex injection into CD32A mice pretreated with effector-deficient humanized AT-10 IgG1 E269R anti-CD32a mAb.

FIG. 14A shows dose-dependent severe thrombocytopenia following intravenous injection of native IV.3 human IgG2 mAbs into CD32A mice but not following intravenous injection of effector-deficient chimeric IV.3 human IgG2 N297A mAbs.

FIG. 14B shows no drop in body temperature of CD32A mice injected with native chimeric IV.3 human IgG2 or with effector-deficient chimeric IV.3 human IgG2 N297A.

FIG. 15A shows flow cytometric analysis of whole blood from CD32A mice prior to injection of native chimeric IV.3 human IgG2 mAbs.

FIG. 15B shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of native chimeric IV.3 human IgG2 mAbs.

FIG. 15C shows flow cytometric analysis of whole blood from CD32A mice prior to injection of effector-deficient chimeric IV.3 human IgG2 N297A mAbs.

FIG. 15D shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of effector-deficient chimeric IV.3 human IgG2 N297A mAbs.

FIG. 16A shows flow cytometric analysis of whole blood from CD32A mice after intravenous injection of IgG immune complexes.

FIG. 16B shows flow cytometric analysis of whole blood from effector-deficient chimeric IV.3 human IgG2 N297A anti-CD32a mAb pre-treated CD32A mice after intravenous injection of IgG immune complexes.

FIG. 17 shows severe thrombocytopenia following intravenous injection of IgG immune complexes into CD32A mice (#1) but not following immune complex injection into CD32A mice pretreated with effector-deficient chimeric IV.3 human IgG2 N297A mAbs (#2-#4).

FIG. 18A shows the presence of occlusive thrombi in the pulmonary blood vessels of CD32A mice after injection of IgG immune complexes.

FIG. 18B shows no thrombosis in the pulmonary blood vessels following IgG immune complex injection into CD32A mice pretreated with effector-deficient chimeric IV.3 human IgG2 N297A anti-CD32a mAbs.

FIG. 18C shows the number of pulmonary thrombi in CD32A mice either treated with vehicle (#1) or with effector-deficient chimeric IV.3 IgG2 N297A anti-CD32a mAbs (#2-#4).

FIG. 19 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or native mouse IV.3 IgG2b (#2) or native chimeric IV.3 human IgG1 (#3) mAbs.

FIG. 20 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or deglycosylated native mouse IV.3 IgG2b mAbs (#2).

FIG. 21 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or native chimeric IV.3 human IgG2 mAbs (#'s 2-4).

FIG. 22 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient chimeric IV.3 human IgG2 N297A anti-CD32a mAbs (#'s 2-3).

FIG. 23 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient chimeric AT-10 human IgG1 E269R anti-CD32a mAbs (#2).

FIG. 24 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient human MDE-8 IgG1 E269R anti-CD32a mAbs (#2). The standard platelet agonist collagen (*) was added to #2 as a positive control in order demonstrate aggregation competence of the platelets.

FIG. 25 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient humanized IV.3.1 IgG1 E269R (here and below, this is “hIV.3.1”) (#2) or native mouse IV.3 IgG2b anti-CD32a mAbs (3 nM) (#3).

FIG. 26 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient humanized IV.3.1 IgG1 E269R (#2) or native mouse IV.3 IgG2b anti-CD32a mAbs (2 nM) (#3). The standard platelet agonist collagen (*) was added to #3 as a positive control in order demonstrate aggregation competence of the platelets.

FIG. 27 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient humanized IV.3.1 IgG1 E269R (6 nM) (#2). The standard platelet agonist collagen (*) was added to #2 as a positive control in order demonstrate aggregation competence of the platelets.

FIG. 28 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient humanized IV.3.1 IgG1 E269R (#2) or native mouse IV.3 IgG2b anti-CD32a mAbs (25 nM) (#3). Buffer (PBS) alone was added as a negative control (#4).

FIG. 29 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient humanized IV.3.1 IgG1 E269R (40 nM) (#2). The standard platelet agonist collagen (*) was added to #2 as a positive control in order demonstrate aggregation competence of the platelets.

FIG. 30 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient humanized IV.3.1 IgG1 E269R (33 nM) (#2) or effector-deficient human MDE-8 IgG1 E269R (50 nM) (#3).

FIG. 31 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or effector-deficient humanized AT-10 IgG1 E269R (“hAT-10”; 15 nM) (#2). F(ab′)2 fragments of goat anti-human-F(ab′)2 (#), which lack an Fc-domain, were added to #2 to demonstrate aggregation competence.

FIG. 32 shows platelet aggregation response to IgG immune complexes in the presence of vehicle (#1) or a combination of effector-deficient humanized IV.3.1 IgG1 E269R, effector-deficient humanized AT-10 IgG1 E269R, and effector-deficient human MDE-8 IgG1 E269R anti-CD32a mAbs (#2). The standard platelet agonist collagen (*) was added to #2 as a positive control in order demonstrate aggregation competence of the platelets.

FIG. 33 shows a lack of platelet aggregation response to a combination of effector-deficient chimeric AT-10 human IgG1 E269R, effector-deficient chimeric IV.3 human IgG2 N297A, and effector-deficient human MDE-8 IgG1 E269R anti-CD32a mAbs.

FIG. 34 shows platelet degranulation in response to IgG antibodies.

FIG. 35 shows platelet degranulation in response to infliximab immune complexes (bar 1) and the protective effect of the effector-deficient antibodies described herein (bars 2-4).

FIG. 36A shows flow cytometric analysis of whole blood from CD32A mice prior to injection of a combination of three effector-deficient anti-CD32a mAbs.

FIG. 36B shows flow cytometric analysis of whole blood from CD32A mice after the injection of a combination of three effector-deficient anti-CD32a mAbs (chimeric AT-10 human IgG1 E269R, chimeric IV.3 human IgG2 N297A, and human MDE-8 IgG1 E269R; 50 μg of each mAb injected).

FIG. 36C shows flow cytometric analysis of whole blood from CD32A mice prior to injection of a combination of three effector-deficient anti-CD32a mAbs.

FIG. 36D shows flow cytometric analysis of whole blood from CD32A mice after the injection of a combination of three effector-deficient anti-CD32a mAbs (chimeric AT-10 human IgG1 E269R, chimeric IV.3 human IgG2 N297A, and human MDE-8 IgG1 E269R; 100 μg of each mAb injected).

FIG. 36E shows no drop in core body temperature of CD32A mice after the injection of a combination of three effector-deficient anti-CD32a mAbs (chimeric AT-10 human IgG1 E269R, chimeric IV.3 human IgG2 N297A, and human MDE-8 IgG1 E269R (denoted “ed-mAbs” in this Figure).

DESCRIPTION OF THE SEQUENCES

Tables 1-5 provide listings of certain sequences referenced herein.

TABLE 1  CDR sequences SEQ ID NO. Description Sequence 1 AT-10 VH Kabat CDR1 AA YYWMN 2 AT-10 VH Kabat CDR2 AA EIRLKSNNYATHYAESVKG 3 AT-10 VH Kabat CDR3 AA RDEYYAMDY 4 AT-10 VL Kabat CDR1 AA RASESVDNFGISFMN 5 AT-10 VL Kabat CDR2 AA GASNQGS 6 AT-10 VL Kabat CDR3 AA QQSKEVPWT 25 IV.3 VH Kabat CDR1 AA NYGMN 26 IV.3 VH Kabat CDR2 AA WLNTYTGESIYPDDFKG 27 IV.3 VH Kabat CDR3 AA GDYGYDDPLDY 28 IV.3 VL Kabat CDR1 AA RSSKSLLHTNGNTYLH 29 IV.3 VL Kabat CDR2 AA RMSVLAS 30 IV.3 VL Kabat CDR3 AA MQHLEYPLT 54 MDE-8 VH Kabat CDR1 AA SYGMH 55 MDE-8 VH Kabat CDR2 AA VIWYDGSNYYYTDSVKG 56 MDE-8 VH Kabat CDR3 AA DLGAAASDY 57 MDE-8 VL Kabat CDR1 AA RASQGINSALA 58 MDE-8 VL Kabat CDR2 AA DASSLES 59 MDE-8 VL Kabat CDR3 AA QQFNSYPHT 73 hAT-10 VH IMGT CDR1 AA GFTFSYYW 74 hAT-10 VH IMGT CDR2 AA IRLKSNNYAT 75 hAT-10 VH IMGT CDR3 AA NRRDEYYAMDY 76 hAT-10 VL IMGT CDR1 AA ESVDNFGISF 77 hAT-10 VL IMGT CDR2 AA GAS 78 hAT-10 VL IMGT CDR3 AA QQSKEVPWT 79 hIV.3.1e VH IMGT CDR1 AA GYTFTNYG 80 hIV.3.1e VH IMGT CDR2 AA LNTYTGES 81 hIV.3.1e VH IMGT CDR3 AA ARGDYGYDDPLDY 82 hIV.3.2b VL IMGT CDR1 AA KSLLHTNGNTY 83 hIV.3.2b VL IMGT CDR2 AA RMS 84 hIV.3.2b VL IMGT CDR3 AA MQHLEYPLT 88 AT-10 VH IMGT CDR1 AA GFTFSYYW 89 AT-10 VH IMGT CDR2 AA IRLKSNNYAT 90 AT-10 VH IMGT CDR3 AA NRRDEYYAMDY 91 AT-10 VL IMGT CDR1 AA ESVDNFGISF 92 AT-10 VL IMGT CDR2 AA GAS 93 AT-10 VL IMGT CDR3 AA QQSKEVPWT 94 MDE-8 VH IMGT CDR1 AA GFTFSSYG 95 MDE-8 VH IMGT CDR2 AA IWYDGSNY 96 MDE-8 VH IMGT CDR3 AA ARDLGAAASDY 97 MDE-8 VL IMGT CDR1 AA QGINSA 98 MDE-8 VL IMGT CDR2 AA DAS 99 MDE-8 VL IMGT CDR3 AA QQFNSYPHT 100 hIV.3.1c VL IMGT CDR1 AA KSLLHTNGNTY 101 hIV.3.1c VL IMGT CDR2 AA RMS 102 hIV.3.1c VL IMGT CDR3 AA MQHLEYPLT

TABLE 2  AT-10 antibody sequences SEQ ID NO. Description Sequence 7 AT-10 VH DNA gaagtgaagcttgaggagtctggaggaggcttggtgcaacctggaggatccat gaaactctcctgtgttgcctctggattcactttcagttactactggatgaactgggt ccgccagtctccagagaaggggcttgagtgggttgctgaaattagattgaaatct aataattatgcaacacattatgcggagtctgtgaaagggaggttcaccatctcaa gagatgattccaaaaataatgtctacctgcaaatgaacaacttaagagctgaaga cactggcatttattactgtaacaggcgtgatgagtattacgctatggattattggg gtcaagggacgtcggtatctgtgtctagt 8 AT-10 VH AA EVKLEESGGGLVQPGGSMKLSCVASGFTFS YY WMN WVRQSPEKGLEWVA EIRLKSNNYATHY AESVKG RFTISRDDSKNNVYLQMNNLRAEDTGI YYCNR RDEYYAMDY WGQGTSVSVSS 9 AT-10 VL DNA gacattgtgctgacccaatctccaggttctttggctgtgtctctagggcagaggg ccaccatctcctgcagagccagcgaaagtgttgataattttggcattagttttatg aactggttccaacagaaaccaggacagccaccccgactcctcatctatggtgca tccaaccaaggatccggggtccctgccaggtttagtggcagtgggtctgggaca gacttcagcctcaacatccatcctgtggaggaggatgatgctgcaatgtatttct gtcagcaaagtaaggaggttccgtggacgttcggtggaggcaccaagctggaa atcaaa 10 AT-10 VL AA DIVLTQSPGSLAVSLGQRATISC RASESVDNFGIS FMN WFQQKPGQPPRLLIY GASNQGS GVPARFS GSGSGTDFSLNIHPVEEDDAAMYFC QQSKEVP WT FGGGTKLEIK 11 hAT-10 VH DNA gaggtgcagctggtggagtctgggggaggcttggtccagcctggagggtccct Variable heavy CDR graft gagactctcctgtgcagcctctggattcaccttctcatactattggatggactggg based on HV3-72*01 HJ3-01 tccgccaggctccagggaaggggctggagtgggttggccgtatcagactgaaa acceptor framework tctaacaactatgccaccgaatacgccgcgtctgtgaaaggcagattcaccatct caagagatgattcaaagaactcactgtatctgcaaatgaacagcctgaaaaccg aggacacggccgtgtattactgtaacagaagagatgagtattacgccatggatta ttggggccaagggacaatggtcaccgtctcttca 12 hAT-10 VH AA EVQLVESGGGLVQPGGSLRLSCAAS GFTFSYYW Variable heavy GDR graft MDWVRQAPGKGLEWVGR IRLKSNNYAT EYAA based on HV3-72*01 HJ3-01 SVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYY acceptor framework C NRRDEYYAMDY WGQGTMVTVSS 13 hAT-10 VL DNA gaaattgtgttgacacagtctccagccaccctgtctttgtctccaggggaaagag Variable light GDR graft ccaccctctcctgcagggccagtgaatctgtggataacttcgggatctccttctta  based on KV3-11*01 KJ1*01 gcctggtaccaacagaaacctggccaggctcccaggctcctcatctatggagc  acceptor framework ctccaacagggccactggcatcccagccaggttcagtggcagtgggtctggga  cagacttcactctcaccatcagcagccragagcctgaagattttgcagtttattac  tgtcagcaatctaaagaggtgccatggaccttcggccaagggaccaaggtgga  aatcaaa 14 hAT-10 VL AA   EIVLTQSPATLSLSLGERATLSCRAS ESVDNFGIS Variable light GDR graft F LAWYQQKPGQAPRLLIY GAS NRATGIPARFSG based on KV3-11*01 KJ1-01 SGSGTDFTLTISSLEPEDFAVYYC QQSKEVPWT F acceptor framework GQGTKVEIK 15 AT-10 HC IgG1 E269R  gaagtgaagcttgaggagtctggaggaggcttggtgcaacctggaggatccat DNA  gaaactctcctgtgttgcctctggattcactttcagttactactggatgaactgggt (including constant  ccgccagtctccagagaaggggcttgagtgggttgctgaaattagattgaaatct region) aataattatgcaacacattatgcggagtctgtgaaagggaggttcaccatctcaa gagatgattccaaaaataatgtctacctgcaaatgaacaacttaagagctgaaga cactggcatttattactgtaacaggcgtgatgagtattacgctatggattattggg gtcaagggacgtcggtatctgtgtctagtgctagcaccaagggcccatcggtctt ccccctggcaccctcctccaagagcacctctgggggcacagcggccctgggct gcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggc gccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactc tactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagac ctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagaaag ttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctg aactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccc tcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccaca gagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg ccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag cgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgca aggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagcc aaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggagg agatgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatccca gcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa gaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagct caccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtga tgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgg gtaaa 16 AT-10 HC IgG1 E269R EVKLEESGGGLVQPGGSMKLSCVASGFTFS YY AA WMN WVRQSPEKGLEWVA EIRLKSNNYATHY (including constant  AESVKG RFTISRDDSKNNVYLQMNNLRAEDTGI region) YYCNR RDEYYAMDY WGQGTSVSVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHRDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK 17 AT-10 HC IgG2 N297A gaagtgaagcttgaggagtctggaggaggcttggtgcaacctggaggatccat DNA gaaactctcctgtgttgcctctggattcactttcagttactactggatgaactgggt (including constant  ccgccagtctccagagaaggggcttgagtgggttgctgaaattagattgaaatct region) aataattatgcaacacattatgcggagtctgtgaaagggaggttcaccatctcaa gagatgattccaaaaataatgtctacctgcaaatgaacaacttaagagctgaaga cactggcatttattactgtaacaggcgtgatgagtattacgctatggattattggg gtcaagggacgtcggtatctgtgtctagtgctagcaccaagggcccatcggtctt ccccctggcgccctgctccaggagcacctccgagagcacagcggccctgggc tgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggc gctctgaccagcggcgtgcacaccttcccagctgtcctacagtcctcaggactc tactccctcagcagcgtggtgaccgtgccctccagcaacttcggcacccagac ctacacctgcaacgtagatcacaagcccagcaacaccaaggtggacaagacag ttgagcgcaaatgttgtgtcgagtgcccaccgtgcccagcaccacctgtggcag gaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctccc ggacccctgaggtcacgtgcgtggtggtggacgtgagccacgaagaccccga ggtccagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaa agccacgggaggagcagttcgccagcacgttccgtgtggtcagcgtcctcacc gttgtgcaccaggactggctgaacggcaaggagtacaagtgcaaggtctccaa caaaggcctcccagcccccatcgagaaaaccatctccaaaaccaaagggcag ccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgacca agaaccaggtcagcctgacctgcctggtcaaaggcttctaccccagcgacatc gccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgc ctcccatgctggactccgacggctccttcttcctctacagcaagctcaccgtgga caagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgagg ctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaa 18 AT-10 HC IgG2 N297A EVKLEESGGGLVQPGGSMKLSCVASGFTFS YY AA WMN WVRQSPEKGLEWVA EIRLKSNNYATHY (including constant  AESVKG RFTISRDDSKNNVYLQMNNLRAEDTGI region) YYCNR RDEYYAMDY WGQGTSVSVSSASTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF GTQTYTCNVDHKPSNTKVDKTVERKCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFASTFRVVSVLTVVHQDWLNGKEYKCKVSNK GLPAPIEKTISKTKGQPREPQVYTLPPSREEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK 19 hAT-10 HC IgG1 E269R gaggtgcagctggtggagtctgggggaggcttggtccagcctggagggtccct DNA gagactctcctgtgcagcctctggattcaccttctcatactattggatggactggg (including constant  tccgccaggctccagggaaggggctggagtgggttggccgtatcagactgaaa region) tctaacaactatgccaccgaatacgccgcgtctgtgaaaggcagattcaccatct caagagatgattcaaagaactcactgtatctgcaaatgaacagcctgaaaaccg aggacacggccgtgtattactgtaacagaagagatgagtattacgccatggatta ttggggccaagggacaatggtcaccgtctcttcagctagcaccaagggcccatc ggtcttccccctggcaccctcctccaagagcacctctgggggcacagcggccc tgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaact caggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctca ggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcac ccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggaca agaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccag cacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaagg acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtga gccacagagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtg cataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgt ggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtaca agtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctcc aaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatccc gggaggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaaca actacaagaccacgcctcccgtgctggactccgacggctccttcttcctctaca gcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgc tccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctg tctccgggtaaa 20 hAT-10 HC IgG1 E269R EVQLVESGGGLVQPGGSLRLSCAAS GFTFSYYW AA MDWVRQAPGKGLEWVGR IRLKSNNYAT EYAA (including constant  SVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYY region) C NRRDEYYAMDY WGQGTMVTVSSASTKGPSV FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHRDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK 21 AT-10 LC kappa DNA gacattgtgctgacccaatctccaggttctttggctgtgtctctagggcagaggg (including constant  ccaccatctcctgcagagccagcgaaagtgttgataattttggcattagttttatg region) aactggttccaacagaaaccaggacagccaccccgactcctcatctatggtgca tccaaccaaggatccggggtccctgccaggtttagtggcagtgggtctgggaca gacttcagcctcaacatccatcctgtggaggaggatgatgctgcaatgtatttct gtcagcaaagtaaggaggttccgtggacgttcggtggaggcaccaagctggaa atcaaacgtacggtggctgcaccatctgtcttcatcttcccgccatctgatgagc agttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatcccaga gaggccaaagtacagtggaaggtggataacgccctccaatcgggtaactccca ggagagtgtcacagagcaggacagcaaggacagcacctacagcctcagcagc accctgacgctgagcaaagcagactacgagaaacacaaagtctacgcctgcga agtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacaggggag agtgt 22 AT-10 LC/ kappa A A DIVLTQSPGSLAVSLGQRATISC RASESVDNFGIS (including constant  FMN WFQQKPGQPPRLLIY GASNQGS GVPARFS region) GSGSGTDFSLNIHPVEEDDAAMYFC QQSKEVP WT FGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQE SVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC EVTHQGLSSPVTKSFNRGEC 23 hAT-10 LC kappa DNA gaaattgtgttgacacagtctccagccaccctgtctttgtctccaggggaaagag (including constant  ccaccctctcctgcagggccagtgaatctgtggataacttcgggatctccttctta region) gcctggtaccaacagaaacctggccaggctcccaggctcctcatctatggagc ctccaacagggccactggcatcccagccaggttcagtggcagtgggtctggga cagacttcactctcaccatcagcagcctagagcctgaagattttgcagtttattac tgtcagcaatctaaagaggtgccatggaccttcggccaagggaccaaggtgga aatcaaacgtacggtggctgcaccatctgtcttcatcttcccgccatctgatgag cagttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatcccag agaggccaaagtacagtggaaggtggataacgccctccaatcgggtaactccc aggagagtgtcacagagcaggacagcaaggacagcacctacagcctcagcag caccctgacgctgagcaaagcagactacgagaaacacaaagtctacgcctgcg aagtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacagggga gagtgt 24 hAT-10 LC kappa AA  EIVLTQSPATLSLSPGERATLSCRAS ESVDNFGIS (including constant  F LAWYQQKPGQAPRLLIY GAS NRATGIPARFSG region) SGSGTDFTLTISSLEPEDFAVYYC QQSKEVPWT F GQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVT HQGLSSPVTKSFNRGEC

TABLE 3  IV.3 antibody sequences SEQ ID NO. Description Sequence 31 IV.3 VH DNA cagatccagttggtgcagtctggacctgagctgaagaagcctggagagacagt caagatctcctgcaaggcttctgggtataccttcacaaactatggaatgaactgg gtgaagcaggctccaggaaagggtttaaagtggatgggctggttaaacacctac actggagagtcaatatatcctgatgacttcaagggacggtttgccttctcttcgga aacctctgccagcactgcctatttgcagatcaacaacctcaaaaatgaggacat ggctacatatttctgtgcaagaggggactatggttacgacgaccctttggactac tggggtcaaggaacctcagtcaccgtctcctca 32 IV.3 VH AA QIQLVQSGPELKKPGETVKISCKASGYTFT NYG MN WVKQAPGKGLKWMG WLNTYTGESIYPD DFKG RFAFSSETSASTAYLQINNLKNEDMATYF CAR GDYGYDDPLDY WGQGTSVTVSS 33 IV.3 VL DNA gacattgtgatgacccaggctgcaccctctgtacctgtcactcctggagagtcag tatccatctcctgcaggtctagtaagagtctcctgcatactaatggcaacacttac ttgcattggttcctacagaggccaggccagtctcctcagctcctgatatatcgga tgtccgtccttgcctcaggagtcccagacaggttcagtggcagtgggtcaggaa ctgctttcacactgagcatcagtagagtggaggctgaggatgtgggtgttttttac tgtatgcaacatctagaatatccgctcacgttcggtgctgggaccaagctggaac tgaaa 34 IV.3 VL AA DIVMTQAAPSVPVTPGESVSISC RSSKSLLHTNG NTYLH WFLQRPGQSPQLLIY RMSVLAS GVPDR FSGSGSGTAFTLSISRVEAEDVGVFYC MQHLEY PLT FGAGTKLELK 35 hIV.3.1e VH DNA caggtgcagctggtgcaatctgggtctgagttgaagaagcctggggcctcagtg Variable heavy CDR graft  aaggtttcctgcaaggcttctggatacaccttcactaactatggtatgaattgggt based on HV7-4-1*2 gcgacaggcccctggacaagggcttgagtggatgggatggctcaacacctaca HJ6*01 acceptor ctggggagtcaacgtatgcccagggcttcacaggacggtttgtcttctccttgga framework cacctctgtcagcacggcatatctgcagatcagcagcctaaaggctgaggaca ctgccgtgtattactgtgcgagaggggactatggttacgacgaccctttggacta ctgggggcaagggaccacggtcaccgtctcctca 36 hIV.3.1e VH AA QVQLVQSGSELKKPGASVKVSCKAS GYTFTNY Variable heavy CDR graft G MNWVRQAPGQGLEWMGW LNTYTGES TYA based on HV7-4-1*2 QGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYY HJ6*01 acceptor C ARGDYGYDDPLDY WGQGTTVTVSS framework 37 hIV.3.2d VH DNA caggtgcagctggtgcagtctggccatgaggtgaagcagcctggggcctcagt Variable heavy CDR graft gaaggtctcctgcaaggcttctgggtataccttcacaaactatggaatgaactgg based on HV7-81*01 gtgaaacaggcccctggacaagggcttaagtggatgggctggttaaacaccta HJ6*01 acceptor cactggagagtcaatatatcctgatgacttcaagggacggtttgccttctccagt framework gacacctctgccagcacagcatacctgcagatcaacaacctaaaggctgagga catggccatgtatttctgtgcgagaggggactatggttacgacgaccctttggac tactgggggcaagggaccacggtcaccgtctcctca 38 hIV.3.2d VH AA QVQLVQSGHEVKQPGASVKVSCKASGYTFT NY Variable heavy CDR graft GMN WVKQAPGQGLKWMG WLNTYTGE SIYP based on HV7-81*01 DDFKG RFAFSSDTSASTAYLQINNLKAEDMAMY HJ6*01 acceptor FCAR GDYGYDDPLDY WGQGTTVTVSS framework 39 hIV.3.1c VL DNA gatattgtgatgacccagactccactctccctgcccgtcacccctggagagccg Variable light CDR graft gcctccatctcctgcaggtctagtaagtctctgctgcataccaacgggaacacct based on KV2-40*01 atttggactggtacctgcagaagccagggcagtctccacagctcctgatctatag KJ4*02 acceptor gatgtcctatcgggcctctggagtcccagacaggttcagtggcagtgggtcagg framework cactgatttcacactgaaaatcagcagggtggaggctgaggatgttggagtttat tactgcatgcagcatctggagtatccactgaccttcggcggagggaccaaggtg gagatcaaa 85 hIV.3.1c VL AA DIVMTQTPLSLPVTPGEPASISCRSS KSLLHTNG Variable light CDR graft NTY LDWYLQKPGQSPQLLIY RMS YRASGVPDR based on KV2-40*01 FSGSGSGTDFTLKISRVEAEDVGVYYC MQHLE KJ4*02 acceptor YPLT FGGGTKVEIK framework 40 hIV.3.2b VL DNA gatattgtgatgacccagactccactctccctgcccgtcacccctggagagccg Variable light CDR graft gcctccatctcctgcaggtctagtaagagtctcctgcatactaatggcaacactt based on KV2-40*01 acttgcattggtacctgcagaagccagggcagtctccacagctcctgatatatcg KJ4*02 acceptor gatgtccgtccttgcctcaggagtcccagacaggttcagtggcagtgggtcagg framework cactgatttcacactgaaaatcagcagggtggaggctgaggatgttggagtttat tactgcatgcaacatctagaatatccgctcacgttcggcggagggaccaaggtg gagatcaaa 41 hIV.3.2b VL AA DIVMTQTPLSLPVTPGEPASISCRSS KSLLHTNG Variable light CDR graft NTY LHWYLQKPGQSPQLLIY RMS VLASGVPDR based on KV2-40*01 FSGSGSGTDFTLKISRVEAEDVGVYYC MQHLE KJ4*02 acceptor YPLT FGGGTKVEIK framework 42 IV.3 HC IgG1 E269R cagatccagttggtgcagtctggacctgagctgaagaagcctggagagacagt DNA caagatctcctgcaaggcttctgggtataccttcacaaactatggaatgaactgg (including constant  gtgaagcaggctccaggaaagggtttaaagtggatgggctggttaaacacctac region) actggagagtcaatatatcctgatgacttcaagggacggtttgccttctcttcgga aacctctgccagcactgcctatttgcagatcaacaacctcaaaaatgaggacat ggctacatatttctgtgcaagaggggactatggttacgcgaccctttggactac tggggtcaaggaacctcagtcaccgtctcctcagctagcaccaagggcccatc ggtcttccccctggcaccctcctccaagagcacctctgggggcacagcggccc tgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaact caggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctca ggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcac ccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggaca agaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccag cacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaagg acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtga gccacagagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtg cataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgt ggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtaca agtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctcc aaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatccc gggaggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaaca actacaagaccacgcctcccgtgctggactccgacggctccttcttcctctaca gcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgc tccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctg tctccgggtaaa 43 IV.3 HCIgGl E269RAA QIQLVQSGPELKKPGETVKISCKASGYTFT NYG (including constant  MN WVKQAPGKGLKWMG WLNTYTGESIYPD region) DFKG RFAFSSETSASTAYLQINNLKNEDMATYF CAR GDYGYDDPLDY WGQGTSVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHRDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK 44 IV.3 HGIgG2 N297A DNA cagatccagttggtgcagtctggacctgagctgaagaagcctggagagacagt (including constant  caagatctcctgcaaggcttctgggtataccttcacaaactatggaatgaactgg region) gtgaagcaggctccaggaaagggtttaaagtggatgggctggttaaacacctac actggagagtcaatatatcctgatgacttcaagggacggtttgccttctcttcgga aacctctgccagcactgcctatttgcagatcaacaacctcaaaatgaggacat ggctacatatttctgtgcaagaggggactatggttacgacgaccctttggactac tggggtcaaggaacctcagtcaccgtctcctcagctagcaccaagggcccatc ggtcttcccctggcgccctgctccaggagcacctccgagagcacagcggccc tgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaact caggcgctctgaccagcggcgtgcacaccttcccagctgtcctacagtcctcag gactctactccctcagcagcgtggtgaccgtgccctccagcaacttcggcaccc agacctacacctgcaacgtagatcacaagcccagcaacaccaaggtggacaag acagttgagcgcaaatgttgtgtcgagtgcccaccgtgcccagcaccacctgtg gcaggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatc tcccggacccctgaggtcacgtgcgtggtggtggacgtgagccacgaagaccc cgaggtccagttcaactggtacgtggacggcgtggaggtgcataatgccaaga caaagccacgggaggagcagttcgccagcacgttccgtgtggtcagcgtcctc accgttgtgcaccaggactggctgaacggcaaggagtacaagtgcaaggtctc caacaaaggcctcccagcccccatcgagaaaaccatctccaaaaccaaaggg cagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatga ccaagaaccaggtcagcctgacctgcctggtcaaaggcttctaccccagcgac atcgccgtggagtgggagagcaatgggcagccggagaacaactacaagacca cgcctcccatgctggactccgacggctccttcttcctctacagcaagctcaccgt ggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatg aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaa 45 IV.3 HC IgG2 N297A AA QIQLVQSGPELKKPGETVKISCKASGYTFT NYG (including constant  MN WVKQAPGKGLKWMG WLNTYTGESIYPD region) DFKG RFAFSSETSASTAYLQINNLKNEDMATYF CAR GDYGYDDPLDY WGQGTSVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNF GTQTYTCNVNHKPSNTKVDKKVERKSCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVQFNWYVDGVEVHNAKTKPREE QFASTYRVVSVLTVVHQDWLNGKEYKCKVSNK GLPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK 46 hIV.3.1e HC IgG1 E269R caggtgcagctggtgcaatctgggtctgagttgaagaagcctggggcctcagtg DNA aaggtttcctgcaaggcttctggatacaccttcactaactatggtatgaattgggt (including constant  gcgacaggcccctggacaagggcttgagtggatgggatggctcaacacctaca region) ctggggagtcaacgtatggcccagggcttcacaggacggtttgtcttctccttgga cacctctgtcagcacggcatatctgcagatcagcagcctaaaggctgaggaca ctgccgtgtattactgtgcgagaggggactatggttacgacgaccctttggacta ctgggggcaagggaccacggtcaccgtctcctcagctagcaccaagggcccat cggtcttccccctggcaccctcctccaagagcacctctgggggcacagcggcc ctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaac tcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctca ggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcac ccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggaca agaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccag cacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaagg acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtga gccacagagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtg gccacagagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtg cataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgt ggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtaca agtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctcc aaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatccc gggaggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaaca actacaagaccacgcctcccgtgctggactccgacggctccttcttcctctaca gcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgc tccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctg tctccgggtaaa 47 hIV.3.1e HC IgG1 E269R QVQLVQSGHEVKQPGETVKISCKAS GYTFTNY AA G MNWVKQAPGKGLKWMGW LNTYTGES TYA (including constant  DFKGRFAFSSDTSASTAYLQINNLKNEDMAMYF region) C ARGDYGYDDPLDY WGQGTTVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHRDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK 48 hIV.3.2d HC IgG1 E269R caggtgcagctggtgcagtctggccatgaggtgaagcagcctggggcctcagt DNA gaaggtctcctgcaaggcttctgggtataccttcacaaactatggaatgaactgg (including constant  gtgaaacaggcccctggacaagggcttaagtggatgggctggttaaacaccta region) cactggagagtcaatatatcctgatgacttcaagggacggtttgccttctccagt gacacctctgccagcacagcatacctgcagatcaacaacctaaaggctgagga catggccatgtatttctgtgcgagaggggactatggttacgacgaccctttggac tactgggggcaagggaccacggtcaccgtctcctcagctagcaccaagggccc atcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcgg ccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtgga actcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcct caggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggc acccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtgga caagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgccc agcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaa ggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgt gagccacagagaccctgaggtcaagttcaactggtacgtggacggcgtggagg tgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgt gtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagta caagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatct ccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatc ccgggaggagatgaccaagaaccagtcagcctgacctgcctggtcaaaggct tctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaa caactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctac agcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatg ctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccct gtctccgggtaaa 49 hIV.3.1d HC IgG1 E269R QVQLVQSGHEVKQPGETVKISCKAS GYTFTNY AA G MNWVKQAPGKGLKWMGW LNTYTGES IYPD (including constant  DFKGRFAFSSDTSASTAYLQINNLKNEDMAMYF region) C ARGDYGYDDPLDY WGQGTTVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHRDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK 50 IV.3 LC kappa DNA gacattgtgatgacccaggctgcaccctctgtacctgtcactcctggagagtcag (including constant  tatccatctcctgcaggtctagtaagagtctcctgcatactaatggcaacacttac region) ttgcattggttcctacagaggccaggccagtctcctcagctcctgatatatcgga tgtccgtccttgcctcaggagtcccagacaggttcagtggcagtgggtcaggaa ctgctttcacactgagcatcagtagagtggaggctgaggatgtgggtgttttttac tgtatgcaacatctagaatatccgctcacgttcggtgctgggaccaagctggaac tgaaacgtacggtggctgcaccatctgtcttcatcttcccgccatctgatgagca gttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatcccagag aggccaaagtacagtggaaggtggataacgccctccaatcgggtaactcccag gagagtgtcacagagcaggacagcaaggacagcacctacagcctcagcagca ccctgacgctgagcaaagcagactacgagaaacacaaagtctacgcctgcgaa gtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacaggggaga gtgt 51 IV.3 LC kappa AA DIVLTQSPGSLAVSLGEPASISCRR KSLLHTING (including constant  NTY LHWLQKPGQSPRLLIY RM S VLASVPDR region) FSGSGTDFTLKISRVEAEDVGVYYC M Q HLE YPL T FGGGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC 86 hIV.31c LC kappa DNA gatattgtgatgacccagactccactctccctgcccgtcacccctggagagccg (including constant  gcctccatctcctgcaggtctagtaagtctctgctgcataccaacgggaacacct region) atttggactggtacctgcagaagccagggcagtctccacagctcctgatctatag gatgtcctatcgggcctctggagtcccagacaggttcagtggcagtgggtcagg cactgatttcacactgaaaatcagcagggtggaggctgaggatgttggagtttat tactgcatgcagcatctggagtatccactgaccttcggcggagggaccaaggtg gagatcaaacgtacggtggctgcaccatctgtcttcatcttcccgccatctgatg agcagttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatccc agagaggccaaagtacagtggaaggtggataacgccctccaatcgggtaactc ccaggagagtgtcacagagcaggacagcaaggacagcacctacagcctcagc agcaccctgacgctgagcaaagcagactacgagaaacacaaagtctacgcctg cgaagtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacaggg gagagtgt 87 hIV.31c LC kappa AA DIVLTQSPGSLAVSLGEPASISCRR KSLLHTING (including constant  NTY LHWLQKPGQSPRLLIY RM S VLASVPDR region) FSGSGTDFTLKISRVEAEDVGVYYC M Q HLE YPL T FGGGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC 52 hIV.3.2b LC kappa DNA gatattgtgatgacccagactccactctccctgcccgtcacccctggagagccg (including constant  gcctccatctcctgcaggtctagtaagtctctgctgcataccaacgggaacacct region) atttggactggtacctgcagaagccagggcagtctccacagctcctgatctatag gatgtcctatcgggcctctggagtcccagacaggttcagtggcagtgggtcagg cactgatttcacactgaaaatcagcagggtggaggctgaggatgttggagtttat tactgcatgcagcatctggagtatccactgaccttcggcggagggaccaaggtg gagatcaaacgtacggtggctgcaccatctgtcttcatcttcccgccatctgatg agcagttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatccc agagaggccaaagtacagtggaaggtggataacgccctccaatcgggtaactc ccaggagagtgtcacagagcaggacagcaaggacagcacctacagcctcagc agcaccctgacgctgagcaaagcagactacgagaaacacaaagtctacgcctg cgaagtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacaggg gagagtgt 53 hIV.3.2b LC kappa AA DIVLTQSPGSLAVSLGEPASISCRR KSLLHTING (including constant  NTY LHWLQKPGQSPRLLIY RM S VLASVPDR region) FSGSGTDFTLKISRVEAEDVGVYYC M Q HLE YPL T FGGGTKVEIKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC

TABLE 4  MDE-8 antibody sequences SEQ ID NO. Description Sequence 60 MDE-8 VH DNA caggcacctggtggagtctgggggaggcgtggtccagcctgggaggtccct  gagactctcctgtgcagcgtctggattcaccttcagtagctatggcatgcactgggtccgccaggc  tccaggcaaggggctggagtgggtggcagttatatggtatgat  ggaagtaattactactatacagnctccgtgaagggccgattcaccatctccagag  acaartccaagaacacgctgtatctgcaaatgaacagcctgagagccgaggac  acggctgtgtattactgtgcgagagatctgggggcagcagcttctgactactgg  ggccagggaaccctggtcaccgtctcctca 61 MDE-8 VH AA QVHLVESGGGVVPGRSLRLSCAASGFTFSSYG MH WVRQAPGKGLEWVA VIWYDGSNYYYTDS VKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARD LGAAASDY WGQGTLVTVSS 62 MDE-8 VL DNA gccatccagttgacccagtctccatcctccctgtctgcatagtaggagacagag  tcaccatcacttgccgggcaagtcagggcattaacagtgctttagcctggtatca  gcagaaaccagggaaagctcctaagctcctgatctargatgcctccagtttgga  aagtggggtcccatcaaggttcagcggcagtggatctgggacagatttcactct caccatcagcagcctgcagcctgaagattttgcaacttattactgtcaacagttta  ataggttaccctcatacttttggccaggggnccaagctggagatcaaa 63 MDE-8 VL AA AIQLTQSPSSLSASVGDRTVTITC RASQGINSALA WYQQKPGKAPKLLIY DASSLES GVPSRRSGSGS GTDFTLTISSLQPEDFATYYC QQFNSYPHT FGQ GTKLEIK 64 MDE-8 HC IgGl E269R DNA caggtgcacctggtggagtctgggggaggcgtggtccagcctgggaggtccct (including constant region) gagactctcctgtgcagcgtctggattcaccttcagtagctatggcatgcactgg gtccgccaggctccaggcaaggggctggagtgggtggcagttatatggtatgat ggaagtaattactactatacagactccgtgaagggccgattcaccatctccagag acaattccaagaacacgctgtatctgcaaatgaacagcctgagagccgaggac acggctgtgtattactgtgcgagagatctgggggcagcagcttctgactactgg ggccagggaaccctggtcaccgtctcctcagctagcaccaagggcccatcggt cttccccctggcaccctcctccaagagcacctctgggggcacagcggccctgg gctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcag gcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcagga ctctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccag acctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagaa agttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacc tgaactcctgggggaccgtcagtcttcctcttccccccaaaacccaccggacac cctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagcca cagagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcata atgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggt cagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagt gcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccggg aggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatc ccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaacta caagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaa gctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccg tgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctc cgggtaaa 65 MDE-8 HC IgG1 E269R AA  QVHLVESGGGVVPGRSLRLSCAASGFTFS SYG (including constant region) MH WVRQAPGKGLEWVA VIWYDGSNYYYTDS VKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARD LGAAASDY WGQGTLVTVSSASTKGPSVFPL APSSLSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHRDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK 66 MDE-8 HC IgG2 N297A DNA  caggtgcacctggtggagtctgggggaggcgtggtccagcctgggaggtccct (including constant region) gagactctcctgtgcagcgtctggattcaccttcagtagctatggcatgcactgg gtccgccaggctccaggcaaggggctggagtgggtggcagttatatggtatgat ggaagtaattactactatacagactccgtgaagggccgattcaccatctccagag acaattccaagaacacgctgtatctgcaaatgaacagcctgagagccgaggac acggctgtgtattactgtgcgagagatctgggggcagcagcttctgactactgg ggccagggaaccctggtcaccgtctcctcagctagcaccaagggcccatcggt cttccccctggcgcctgctccaggagcacctccgagagcacagcggccctgg gctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcag gcgctctgaccagcggcgtgcacaccttcccagctgtcctacagtcctcaggac tctactccctcagcagcgtggtgaccgtgccctccagcaacttcggcacccaga cctacacctgcaacgtagatcacaagcccagcaacaccaaggtggacaagaca gttgagcgcaaatgttgtgtcgagtgcccaccgtgcccagcaccacctgtggca ggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcc cggacccctgaggtcacgtgcgtggtggtggacgtgagccacgaagaccccg aggtccagttcaactggtacgtggacggcgtggaggtgcataatgccaagaca aagccacgggaggagcagttcgccagcacgttccgtgtggtcagcgtcctcac cgttgtgcaccaggactggctgaacggcaaggagtacaagtgcaaggtctcca acaaaggcctcccagcccccatcgagaaaaccatctccaaaaccaaagggca gccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgacc aagaaccaggtcagcctgacctgcctggtcaaaggcttctaccccagcgacatc gccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgc ctcccatgctggactccgacggctccttcttcctctacagcaagctcaccgtgga caagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgagg ctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaa 67 MDE-8 HC IgG2 N297A AA QVHLVESGGGVVPGRSLRLSCAASGFTFS SYG (including constant region) MH WVRQAPGKGLEWVA VIWYDGSNYYYTDS VKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC AR D LGAAASDY WGQGTLVTVSSASTKGPSVFPL APSSLSTSGGTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YTCNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQFAS TFRVVSVLTVLHQDWLNGKEYKCKVSNKGLPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPP MLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK 68 MDE-8 LC kappa DNA gccatccagttgacccagtctccatcctccctgtctgcatctgtaggagacagag (including constant region) tcaccatcacttgccgggcaagtcagggcattaacagtgctttagcctggtatca gcagaaaccagggaaagctcctaagctcctgatctatgatgcctccagtttgga aagtggggtcccatcaaggttcagcggcagtggatctgggacagatttcactct caccatcagcagcctgcagcctgaagattttgcaacttattactgtcaacagttta atagttaccctcatacttttggccaggggaccaagctggagatcaaacgtacggt ggctgcaccatctgtcttcatcttcccgccatctgatgagcagttgaaatctggaa ctgcctctgttgtgtgcctgctgaataacttctatcccagagaggccaaagtaca gtggaaggtggataacgccctccaatcgggtaactcccaggagagtgtcacag agcaggacagcaaggacagcacctacagcctcagcagcaccctgacgctgag caaagcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagg gcctgagctcgcccgtcacaaagagcttcaacaggggagagtgt 69 MDE-8 LC kappa AA AIQLTQSPSSLSASVGDRTVTITC RASQGINSALA (including constant region) WYQQKPGKAPKLLIY DASSLES GVPSRRSGSGS GTDFTLTISSLQPEDFATYYC QQFNSYPHT FGQ GTKLEIKRTVAAPSVFIFPPSDEQLKGTASVVC LLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ GLSSPVTKSFNRGEC

TABLE 5  other sequences SEQ ID NO. Description Sequence 70 NP_001129691.1 MTMETQMSQNVCPRNLWLLQPLTVLLLL CD32a-H131  ASADSQAAAPPKAVLKLEPPWINVLQED [Homo sapiens] SVTLTCQGARSPESDSIQWFHNGNLIPT HTQPSYRFKANNNDSGEYTCQTGQTSLS DPVHLTVLSEWLVLQTPHLEFQEGETIM LRCHSWKDKPLVKVTFFQNGKSQKFS H L DPTFSIPQANHSHSGDYHCTGNIGYTLF SSKPVTITVQVPSMGSSSPMGIIVAVVI ATAVAAIVAAVVALIYCRKKRISANSTD PVKAAQFEPPGRQMIAIRKRQLEETNND YETADGGYMTLNPRAPTDDDKNIYLTLP PNDHVNSNN 71 NP_001129691.1: MTMETQMSQNVCPRNLWLLQPLTVLLLL p.His167 ASADSQAAAPPKAVLKLEPPWINVLQED Arg CD32a-R131  SVTLTCQGARSPESDSIQWFHNGNLIPT [Homo sapiens] HTQPSYRFKANNNDSGEYTCQTGQTSLS DPVHLTVLSEWLVLQTPHLEFQEGETIM LRCHSWKDKPLVKVTFFQNGKSQKFS R L DPTFSIPQANHSHSGDYHCTGNIGYTLF SSKPVTITVQVPSMGSSSPMGIIVAVVI ATAVAAIVAAVVALIYCRKKRISANSTD PVKAAQFEPPGRQMIAIRKRQLEETNND YETADGGYMTLNPRAPTDDDKNIYLTLP PNDHVNSNN 72 NP_003992.3  MGILSFLPVLATESDWADCKSPQPWGHM CD32b isoform 1 LLWTAVLFLAPVAGTPAAPPKAVLKLEP [Homo sapiens] QWINVLQEDSVTLTCRGTHSPESDSIQW FHNGNLIPTHTQPSYRFKANNNDSGEYT CQTGQTSLSDPVHLTVLSEWLVLQTPHL EFQEGETIVLRCHSWKDKPLVKVTFFQN GKSKKFSRSDPNFSIPQANHSHSGDYHC TGNIGYTLYSSKPVTITVQAPSSSPMGI IVAVVTGIAVAAIVAAVVALIYCRKKRI SALPGYPECREMGETLPEKPANPTNPDE ADKVGAENTITYSLLMHPDALEEPDDQN RI

DESCRIPTION OF THE EMBODIMENTS

In one embodiment, a method for treating a CD32a-mediated disease or disorder in a human subject is encompassed, wherein a therapeutically effective amount of one or more effector-deficient anti-CD32a monoclonal antibodies as described herein, is administered to a human subject, thereby treating the CD32a-mediated disease or disorder.

In one embodiment, the anti-CD32a monoclonal antibody is capable of 1) preventing activation of CD32a by IgG immune complexes; and 2) has an Fc region that has been altered so as to reduce or eliminate Fc-binding to CD16, CD32, or CD64 type IgG receptors.

In one embodiment, the anti-CD32a monoclonal antibody is capable of 1) preventing activation of CD32a by IgG immune complexes; and 2) has an Fc region that has been altered so as to reduce or eliminate Fc-binding to CD16, CD32, and CD64 type IgG receptors.

In one embodiment, the reduction in Fc-binding to CD16, CD32, and/or CD64 is a complete reduction as compared to an effector-competent antibody control. In other aspects, the reduction in about 50%, about 60%, about 70%, about 80%, about 90%, or about 95%, or more, as compared to an effector-competent antibody control.

Antibodies

Any effector-deficient anti-CD32a antibody may be used in the method embodiments. The antibodies of the composition and method embodiments comprise at least a portion of the Fc region.

In one embodiment, the effector-deficient antibody is an AT-10, IV.3, or MDE-8 antibody comprising one or more of the CDRs described for each antibody, respectively, as in Tables 1-5, and is effector-deficient. In other embodiments, the effector-deficient antibody is an AT-10, IV.3, or MDE-8 antibody comprising the variable heavy and light chains described for each antibody, respectively, as in Tables 1-5, and is effector-deficient. In other embodiments, the effector-deficient antibody is an AT-10, IV.3, or MDE-8 antibody comprising the full-length heavy and full-length light chains described for each antibody, respectively, as in Tables 1-5, and is effector-deficient.

In one embodiment, the effector-deficient antibody is an AT-10, IV.3, or MDE-8 antibody comprising one or more of the CDRs of that antibody, wherein the CDRs are identical to the CDR sequences described for each antibody, respectively, in Tables 1-5, or wherein one, two, or three of the CDRs have 1 or 2 mutations as compared to the sequences described for each antibody, as in Table 1, and is effector-deficient.

In other embodiments, the effector-deficient antibody is an AT-10, IV.3, or MDE-8 antibody comprising the variable heavy and light chains described in Tables 1-5 for each antibody, respectively, wherein the variable heavy and light chains are 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the variable heavy and variable light chains described in Tables 1-5 for each antibody, respectively, and wherein the antibody is effector-deficient.

In other embodiments, the effector-deficient antibody is an AT-10, IV.3, or MDE-8 antibody comprising a full length heavy and light chain described in Tables 1-5 for each antibody, respectively, or a variable heavy and light chain that is 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99° A identical to a heavy and light chain described in Tables 1-5 for each antibody, respectively, and is effector-deficient.

The antibody compositions of the invention, as well as the antibodies used in the methods and uses described herein, are capable of preventing activation of CD32a by IgG immune complexes. Whether an antibody is capable of preventing activation of CD32a by IgG immune complexes can be tested by methods well known in the art, namely, by testing washed platelets for aggregation or degranulation responses to IgG immune complexes, as per the “IgG Immune Complex Test” described below. See, e.g., Meyer T et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice (January 2009) J Thromb Haemost 7:171; PubMed ID: 18983497.

“IgG Immune Complex Test”: The following steps can determine whether an antibody can prevent activation of CD32a by IgG immune complexes. First, for example, human platelets can be isolated from other blood cells by “washing” methods (see, e.g., Meyer T et al. (January 2009) J Thromb Haemost 7:171; PubMed ID: 18983497). Alternatively, platelets from FCGR2A transgenic mice can be isolated using similar methods (see, e.g., Robles-Carrillo L et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice (August 2010) J Immunol 185:1577; PubMed ID: 20585032). Second, such washed platelets can then be used to test for CD32a-mediated activation by IgG antibodies known to activate human CD32a, for example anti-CD9 mAb (e.g., as in PubMed ID: 18983497, op cit), or anti-CD40L mAb, M90 (e.g., as in PubMed ID: 20585032, op di). In order to activate CD32a on washed platelets, some antibodies may need to be clustered by antigen so as to form an immune complex (IC), as is the case for M90, which is combined with CD40L prior to exposure to washed platelets. CD32a-activating antibodies can be identified using a platelet aggregometer, such as a Chrono-Log model 490 series aggregometer. If the antibody causes platelet aggregation after introduction into the aggregometer cuvette, and such aggregation is prevented by an anti-CD32a blocking antibody (e.g., such as IV.3, AT-10, or MDE-8; many others are commercially available and are known to those skilled in the art), then the antibody specifically activates platelet CD32a and is therefore sufficient for use as a required reagent in the “IgG Immune Complex Test”. An alternative to the washed platelet aggregation test is the serotonin release assay (or “SRA”), which measures platelet degranulation (see, e.g., PubMed IDs 18983497 and 20585032 op cit). CD32a is the only IgG receptor on human platelets; therefore, these tests are capable of specifically identifying CD32a-activating antibodies. The third step in the “IgG Immune Complex Test” requires exposure of washed platelets to candidate anti-CD32a antibodies prior to introduction of the CD32a-activating IgG antibody. For example, washed human platelets suspended in assay buffer (typically, 250/nanoliter) are placed in an aggregometer cuvette. The instrument settings are adjusted so as to establish an assay signal range and baseline. Next, the candidate anti-CD32a blocking antibody (e.g., IV.3, AT-10, or MDE-8) is introduced into the cuvette (typically at or near 10 micrograms per milliliter). Next, the platelet activating IgG antibody or IgG immune complex (e.g., M90+CD40L, typically at 50-500 nM final assay concentration) is added to the platelet suspension in the cuvette. Finally, platelet aggregation is monitored for at least one minute (or, typically, more than five minutes) to assess whether the anti-CD32a mAb prevents IgG antibody/immune complex-induced platelet aggregation. If an anti-CD32a antibody, using these steps, can prevent the activation of CD32a by IgG antibodies or IgG immune complexes, as evidenced by inhibition of aggregation (or degranulation if the SRA is used), then the anti-CD32a antibody satisfies the “IgG Immune Complex Test”. Similarly, if an anti-CD32a antibody lacks the capacity to prevent platelet aggregation and degranulation, said anti-CD32a antibody fails to satisfy the “IgG Immune Complex Test”.

In the Examples included herein, FIGS. 19-33 demonstrate by washed platelet aggregation (i.e., using the “IgG Immune Complex Test”) that mouse IV.3, chimeric IV.3, and humanized IV.3, that chimeric AT-10 and humanized AT-10, and that human MDE-8 IgG anti-CD32a mAbs all satisfy the “IgG Immune Complex Test”, regardless of whether such anti-CD32a antibodies are of the IgG1 or IgG2 isotype subclass, and regardless of whether such anti-CD32a mAbs have native or effector-deficient Fc regions. As an alternative to the use of platelet aggregation as an “IgG Immune Complex Test”, FIGS. 34 and 35 demonstrate similar results for IV.3, AT-10, and MDE-8 antibody variants using the SRA instead of platelet aggregation; here also, all tested antibodies prevent IC-induced platelet activation and therefore satisfy the “IgG Immune Complex Test”.

a. Effector-Deficiency

The antibody compositions of the invention, as well as the antibodies used in the methods and uses described herein, are “effector-deficient.” As used herein, an “effector-deficient” antibody is defined as an antibody having an Fc region that has been altered so as to reduce or eliminate Fc-binding to CD16, CD32, and/or CD64 type IgG receptors.

In one embodiment, the reduction in Fc-binding to CD16, CD32, and/or CD64 is a complete reduction as compared to an effector-competent control. In other aspects, the reduction in about 50%, about 60%, about 70%, about 80%, about 90%, or about 95%, or more, as compared to an effector-competent antibody control. Methods for determining whether an antibody has a reduced Fc-binding to CD16, CD32, and/or CD64 are well known in the art. See, e.g., US20110212087 A1, WO 2013165690, and Vafa O. et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations (January 2014) Methods 65:114; PubMed ID: 23872058.

In further embodiments, an effector-deficient anti-CD32a antibody is an antibody that is capable of 1) preventing activation of CD32a by IgG immune complexes; 2) has an Fc region that has been altered so as to reduce or eliminate Fc-binding to CD16, CD32, and/or CD64 type IgG receptors; and 3) does not induce Fc-mediated adverse host reactions following administration.

Whether the anti-CD32a effector-deficient antibodies of the present invention are capable of inducing an adverse host reaction following administration can be tested by the “Immobilized IgG Test” described below.

“Immobilized IgG Test”: The following steps can determine whether an anti-CD32a antibody is capable of inducing an IgG-mediated adverse reaction following intravenous administration into a host animal. The host animal must be a mammal and must display CD32 IgG receptors having at least one epitope to which the anti-CD32a antibody to be tested is known to bind as an antigen. For example, IV.3 is an IgG mAb known to bind CD32a antigen (e.g., as in SEQ ID NO: 70, and as in SEQ ID NO: 71; see, e.g., Rosenfeld S I et al. Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes (December 1985) J Clin Invest 76:2317; PubMed ID: 2934409); AT-10 is an IgG mAb known to bind CD32 antigen (e.g., as in SEQ ID NOs: 70-72; see e.g., Greenman J et al. Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab′)2 derivative for recruitment of cytotoxic effectors (November 1991) Mol Immunol 28:1243; PubMed ID: 1835758); and MDE-8 is an IgG mAb known to bind CD32 antigen (e.g., as in SEQ ID NOs: 70-72; see e.g., van Royen-Kerkhof A et al. A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice (July 2005) Br J Haematol 130:130; PubMed ID: 15982355). One suitable host animal for use in the “Immobilized IgG Test” for anti-CD32a mAbs is the FCGR2A mouse (“B6;SJL-Tg(FCGR2A)11Mkz/J” mice, #003542, The Jackson Laboratory, Bar Harbor, Me., USA). Other suitable CD32-positive host animals are known to those skilled in the art. The “Immobilized IgG Test” is then conducted by, for example, injecting the purified anti-CD32a test antibody (preferably in physiologic saline, phosphate buffered saline, or another suitably inert vehicle) into the tail vein of (in this case) the FCGR2A (i.e., CD32A) mouse. Typically, 50-100 micrograms is injected; however, lack of reaction may suggest greater quantities of antibody should be injected: for example, 120 micrograms or 140 micrograms may be required to elicit a reaction. Quantities greater than 150 micrograms are typically not required for FCGR2A mice. Immediately following injection of the test antibody (in this example, the anti-CD32a mAb), the animal in monitored for core body temperature (typically, using a rectal thermometer) every 10 minutes for at least 20 minutes post injection (baseline temperature is established prior to test mAb injection). A temperature drop of more than two degrees celcius (i.e., hypothermia) that is sustained for more than five minutes, represents an adverse reaction indicating that the anti-CD32a test mAb failed to satisfy the “Immobilized IgG Test”. Additionally, at least twenty minutes after injection of the anti-CD32a test mAb, and preferably thirty minutes after injection of the anti-CD32a test mAb, whole blood is collected from the host animal (retro-orbitally, or by venipuncture) and analyzed to assess changes in the number of circulating target cells. Cell counts can be obtained by flow cytometry, by automated cell counter, or by use of a hemocytometer. In the case of testing anti-CD32a mAbs in FCGR2A mice, baseline platelet counts are obtained on the day prior to testing, or at least one to three hours prior to injection of the anti-CD32a test mAb. Note that the process of blood draw, and in particular serial blood draws, can reduce apparent cell counts. Typically, baseline platelet counts in FCGR2A mice will exceed 700 per nanoliter, and are more typically greater than 800 per nanoliter, and may be as high as 1200, 1500, 1800, or 2000 per nanoliter. In the case of testing anti-CD32a mAbs in FCGR2A (CD32A) mice, a drop in circulating platelet counts of greater than 50% represents an adverse reaction indicating that the anti-CD32a test mAb failed to satisfy the “Immobilized IgG Test”. In contrast, if 50 or more micrograms of an anti-CD32a mAb is intravenously injected into CD32A mice and core body temperature does not drop more than two degrees celcius for more than five minutes and circulating platelet counts are not reduced by more than 50% within thirty minutes, the anti-CD32a antibody satisfies the “Immobilized IgG Test”.

In the Examples included herein, FIGS. 1-17 and FIG. 36 demonstrate (i.e., using the “Immobilized IgG Test”) that effector-deficient but not native formats of chimeric IV.3, chimeric AT-10, humanized AT-10, and human MDE-8 IgG anti-CD32a mAbs satisfy the “Immobilized IgG Test”, regardless of whether such anti-CD32a antibodies are of the IgG1 or IgG2 isotype subclass. Notably, all native anti-CD32a IgG mAbs tested by the “Immobilized IgG Test” failed to satisfy the “Immobilized IgG Test” in these examples, while all effector-deficient anti-CD32a IgG mAbs tested by the “Immobilized IgG Test” satisfied the “Immobilized IgG Test”.

Methods for engineering effector-deficient antibodies with reduced capacity for Fc-dependent binding to CD16, CD32, and/or CD64 are well known in the art. For example, in order to achieve this result, an effector-deficient antibody may have one or more of the following mutations: E233P, G237M, D265A, D265N, E269R, D270A, D270N, N297A, N297Q, N297D, N297R, S298N, T299A (numbering is EU index of Kabat).

In certain embodiments, the Fc region mutation is selected from M252Y+S254T+T256E, G385D+Q386P+N389S, and H433K+N434F+Y436H, which are mutations known to extend circulating half-life of the therapeutic antibody (see, e.g., U.S. Pat. No. 8,323,962).

In certain embodiments, the anti-CD32a mAbs of the invention are modified to remove T-cell epitopes, which are known in the art to promote immunogenicity.

1. Effector-Deficient AT-10 Monoclonal Antibodies

In one embodiment, the effector-deficient anti-CD32a antibody is an effector-deficient AT-10 antibody. In one aspect, the AT-10 antibody comprises:

-   -   a. a heavy chain variable region CDR1 sequence comprising a         sequence that is identical to the sequence YYWMN (SEQ ID NO: 1)         or GFTFSYYW (SEQ ID NO: 73 and SEQ ID NO: 88), or is a sequence         having 1 amino acid difference as compared to YYWMN (SEQ ID         NO: 1) or GFTFSYYW (SEQ ID NO: 73 and SEQ ID NO: 88);     -   b. a heavy chain variable region CDR2 sequence comprising a         sequence that is identical to the sequence EIRLKSNNYATHYAESVKG         (SEQ ID NO: 2) or IRLKSNNYAT (SEQ ID NO: 74 and SEQ ID NO: 89),         or is a sequence having 1 or 2 amino acid differences as         compared to EIRLKSNNYATHYAESVKG (SEQ ID NO: 2) or IRLKSNNYAT         (SEQ ID NO: 74 and SEQ ID NO: 89);     -   c. a heavy chain variable region CDR3 sequence comprising a         sequence that is at identical to the sequence RDEYYAMDY (SEQ ID         NO: 3) or NRRDEYYAMDY (SEQ ID NO: 75 and SEQ ID NO: 90), or is a         sequence having 1 or 2 amino acid differences as compared to         RDEYYAMDY (SEQ ID NO: 3) or NRRDEYYAMDY (SEQ ID NO: 75 and SEQ         ID NO: 90);     -   d. a light chain variable region CDR1 sequence comprising a         sequence that is at identical to the sequence RASESVDNFGISFMN         (SEQ ID NO: 4) or ESVDNFGISF (SEQ ID NO: 76 and SEQ ID NO: 91),         or is a sequence having 1 or 2 amino acid differences as         compared to RASESVDNFGISFMN (SEQ ID NO: 4) or ESVDNFGISF (SEQ ID         NO: 76 and SEQ ID NO: 91;     -   e. a light chain variable region CDR2 sequence comprising a         sequence that is at identical to the sequence GASNQGS (SEQ ID         NO: 5) or GAS (SEQ ID NO: 77 and SEQ ID NO: 92), or is a         sequence having 1 or 2 amino acid differences as compared to         GASNQGS (SEQ ID NO: 5) or GAS (SEQ ID NO: 77 and SEQ ID NO: 92);         and     -   f. a light chain variable region CDR3 sequence comprising a         sequence that is identical to the sequence QQSKEVPWT (SEQ ID         NO: 6) or QQSKEVPWT (SEQ ID NO:78 and SEQ ID NO: 93), or is a         sequence having 1 or 2 amino acid differences as compared to         QQSKEVPWT (SEQ ID NO: 6) or QQSKEVPWT (SEQ ID NO:78 and SEQ ID         NO: 93.

In other aspects, the effector-deficient AT-10 antibody comprises a variable heavy chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 8, and a variable light chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 10.

In other aspects, the effector-deficient AT-10 antibody comprises:

-   -   a. a heavy chain sequence that is at least 75%, 80%, 85%, 90%,         95%, 96%, 97%, 98%, or 99% identical to the sequence shown in         SEQ ID NO: 16 or SEQ ID NO: 18; and     -   b. a light chain sequence that is at least 75%, 80%, 85%, 90%,         95%, 96%, 97%, 98%, or 99% identical to the sequence shown in         SEQ ID NO: 22.

In another embodiment, the effector-deficient humanized AT-10 antibody comprises a variable heavy chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 12; and a variable light chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 14.

In another aspect, the effector-deficient humanized AT-10 antibody comprises:

a heavy chain sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 20; and

a light chain sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 24.

2. Effector-Deficient IV.3 Monoclonal Antibodies

In one embodiment, the effector-deficient anti-CD32a antibody is an effector-deficient IV.3 antibody. In one aspect, the IV.3 antibody comprises:

-   -   a. a heavy chain variable region CDR1 sequence comprising a         sequence that is at identical to the sequence NYGMN (SEQ ID         NO: 25) or GYTFTNYG (SEQ ID NO: 79), or is a sequence having 1         or 2 amino acid differences as compared to the sequence NYGMN         (SEQ ID NO: 25) or GYTFTNYG (SEQ ID NO: 79);     -   b. a heavy chain variable region CDR2 sequence comprising a         sequence that is identical to the sequence WLNTYTGESIYPDDFKG         (SEQ ID NO: 26) or LNTYTGES (SEQ ID NO: 80), or is a sequence         having 1 or 2 amino acid differences as compared to the sequence         WLNTYTGESIYPDDFKG (SEQ ID NO: 26) or LNTYTGES (SEQ ID NO: 80);     -   c. a heavy chain variable region CDR3 sequence comprising a         sequence that is identical to the sequence GDYGYDDPLDY (SEQ ID         NO: 27) or ARGDYGYDDPLDY (SEQ ID NO: 81), or is a sequence         having 1 or 2 amino acid differences as compared to the sequence         GDYGYDDPLDY (SEQ ID NO: 27) or ARGDYGYDDPLDY (SEQ ID NO: 81);     -   d. a light chain variable region CDR1 sequence comprising a         sequence that is identical to the sequence RSSKSLLHTNGNTYLH (SEQ         ID NO: 28) or KSLLHTNGNTY (SEQ ID NO: 82 and SEQ ID NO: 100), or         is a sequence having 1 or 2 amino acid differences as compared         to the sequence RSSKSLLHTNGNTYLH (SEQ ID NO: 28) or KSLLHTNGNTY         (SEQ ID NO: 82 and SEQ ID NO: 100);     -   e. a light chain variable region CDR2 sequence comprising a         sequence that is identical to the sequence RMSVLAS (SEQ ID         NO: 29) or RMS (SEQ ID NO: 83 and SEQ ID NO: 101), or is a         sequence having 1 or 2 amino acid differences as compared to the         sequence RMSVLAS (SEQ ID NO: 29) or RMS (SEQ ID NO: 83 and SEQ         ID NO: 101); and     -   f. a light chain variable region CDR3 sequence comprising a         sequence that is identical to the sequence MQHLEYPLT (SEQ ID         NO: 30) or MQHLEYPLT (SEQ ID NO: 84 and SEQ ID NO: 102), or is a         sequence having 1 or 2 amino acid differences as compared to the         sequence MQHLEYPLT (SEQ ID NO: 30) or MQHLEYPLT (SEQ ID NO: 84         and SEQ ID NO: 102).

In other aspects, the effector-deficient IV.3 antibody comprises a variable heavy chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 32; and a variable light chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 34.

In other aspects, the effector-deficient IV.3 antibody comprises:

-   -   a. a heavy chain sequence comprising a sequence that is at least         75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the         sequence shown in SEQ ID NO: 43 or SEQ ID NO: 45, and     -   b. a light chain sequence comprising a sequence that is at least         75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the         sequence shown in SEQ ID NO: 51.

In one embodiment, the effector-deficient IV.3 antibody is a humanized antibody comprising a variable heavy chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO:36 or SEQ ID NO: 38; and a variable light chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 41 or SEQ ID NO: 85.

In certain embodiments, the effector-deficient humanized IV.3 antibody comprises:

-   -   a. a heavy chain sequence that is at least 75%, 80%, 85%, 90%,         95%, 96%, 97%, 98%, or 99% identical to the sequence shown in         SEQ ID NO: 47 or SEQ ID NO: 49; and     -   b. a light chain sequence that is at least 75%, 80%, 85%, 90%,         95%, 96%, 97%, 98%, or 99% identical to the sequence shown in         SEQ ID NO: 53 or SEQ ID NO: 87.

3. Effector-Deficient MDE-8 Monoclonal Antibodies

In some aspects, the effector-deficient anti-CD32a antibody is an effector-deficient MDE-8 antibody. In some aspects the effector-deficient MDE-8 antibody comprises:

-   -   a. a heavy chain variable region CDR1 sequence comprising a         sequence that is identical to the sequence SYGMH (SEQ ID NO: 54)         or GFTFSSY (residues 1-7 of SEQ ID NO: 94), or is a sequence         having 1 or 2 amino acid differences as compared to the sequence         SYGMH (SEQ ID NO: 54) or GFTFSSY (residues 1-7 of SEQ ID NO:         94);     -   b. a heavy chain variable region CDR2 sequence comprising a         sequence that is identical to the sequence VIWYDGSNYYYTDSVKG         (SEQ ID NO: 55) or IWYDGSNY (SEQ ID NO: 95), or is a sequence         having 1 or 2 amino acid differences as compared to the sequence         VIWYDGSNYYYTDSVKG (SEQ ID NO: 55) or IWYDGSNY (SEQ ID NO: 95;     -   c. a heavy chain variable region CDR3 sequence comprising a         sequence that is identical to the sequence DLGAAASDY (SEQ ID         NO: 56) or ARDLGAAASDY (SEQ ID NO: 96), or is a sequence having         1 or 2 amino acid differences as compared to the sequence         DLGAAASDY (SEQ ID NO: 56) or ARDLGAAASDY (SEQ ID NO: 96);     -   d. a light chain variable region CDR1 sequence comprising a         sequence that is identical to the sequence RASQGINSALA (SEQ ID         NO: 57) or QGINSA (SEQ ID NO: 97), or is a sequence having 1 or         2 amino acid differences as compared to the sequence RASQGINSALA         (SEQ ID NO: 57) or QGINSA (SEQ ID NO: 97);     -   e. a light chain variable region CDR2 sequence comprising a         sequence that is identical to the sequence DASSLES (SEQ ID         NO: 58) or DAS (SEQ ID NO: 98), or is a sequence having 1 amino         acid differences as compared to the sequence DASSLES (SEQ ID         NO: 58) or DAS (SEQ ID NO: 98); and     -   f. a light chain variable region CDR3 sequence comprising a         sequence that is identical to the sequence QQFNSYPHT (SEQ ID         NO: 59) or QQFNSYPHT (SEQ ID NO: 99), or is a sequence having 1         or 2 amino acid differences as compared to the sequence         QQFNSYPHT (SEQ ID NO: 59) or QQFNSYPHT (SEQ ID NO: 99).

In other aspects, the effector-deficient MDE-8 antibody comprises a variable heavy chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 61; and a variable light chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 63.

In one embodiment, the effector-deficient anti-CD32a antibody is an effector-deficient anti-MDE8 antibody comprising:

-   -   a. a heavy chain sequence that is at least 75%, 80%, 85%, 90%,         95%, 96%, 97%, 98%, or 99% identical to the sequence shown in         SEQ ID NO: 65 or SEQ ID NO: 67; and     -   b. a light chain sequence that is at least 75%, 80%, 85%, 90%,         95%, 96%, 97%, 98%, or 99% identical to the sequence shown in         SEQ ID NO: 69.

The antibodies of the composition and method embodiments may be fully human, humanized, chimeric, recombinant, or synthetic.

In some aspects, the invention comprises an isolated antibody that competes for binding to CD32a with an effector-deficient antibody disclosed herein.

In some aspects, the invention comprises a pharmaceutical composition comprising an effector-deficient anti-CD32a antibody as described herein.

In one embodiment, the effector-deficient anti-CD32a antibody is an effector-deficient MDE-8, IV.3, or AT-10 monoclonal antibody. In one embodiment, the effector-deficient MDE-8, IV.3, or AT-10 monoclonal antibody is humanized.

An effector deficient anti-CD32a monoclonal antibody that specifically binds CD32a comprising at least a portion of an Fc domain that is mutated at one or more amino acids, wherein the mutation prevents Fc-mediated binding to CD16, CD32, or CD64 IgG receptors is encompassed.

b. Further Antibody Embodiments

The antibodies in the composition and method embodiments may exhibit any or all of the following functional features:

-   -   a. the antigen-binding portions of the antibodies bind human         CD32a with an equilibrium affinity constant value (“K_(D)”)         stronger (less than) than 10⁻⁸M when in aqueous solution;     -   b. the antigen-binding portions of the antibodies bind human         CD32 where such binding inhibits stable interactions between         such bound-CD32 and the Fc-region of any human or therapeutic         IgG molecule where such human or therapeutic IgG molecule is         either: (1) bound in a Fab-dependent manner to at least one         antigen molecule, or (2) clustered into an assembly of at least         two such human or therapeutic IgG molecules, or (3) localized to         a surface in such a manner so as to restrict aqueous diffusion         of the human or therapeutic IgG molecule;     -   c. the antibodies include at least a portion of an Fc-region,         and either lack the capacity, or have reduced capacity, for         Fc-region binding to human IgG receptors (FcgammaRs) of         classical types I (CD64), II (CD32), or III (CD16), where such         reduced or absent binding is comparatively more than 20%, 30%,         40%, 45%, or 50% weaker than that of corresponding naturally         occurring classical IgG-Fc-regions (i.e., either of IgG1, IgG2,         IgG3, or IgG4), where any such classical IgG-Fc-region exhibits         binding to CD16, CD32, or CD64.

The antibodies in the composition and method embodiments may exhibit any or all of the following structural features:

-   -   a. The antibodies comprise, consist, or consist essentially of         (in terms of amino acid composition) the following arrangement         of a total of four polypeptides per single IgG molecule:         -   i. two heavy chain polypeptides covalently bound together by             at least two cysteine-to-cysteine disulfide bonds, wherein             such interchain disulfide bonds are located in or near the             hinge region, and wherein such heavy chain polypetpides are             of the IgG isotype (class 1, 2, 3, or 4, or any hybrid             version comprising segments of the same) of heavy chain             immunoglobulin molecule, and where each such heavy chain             polypeptide is comprised of at least a portion of one             variable domain (VH) and one, two, or three constant domains             (CH1, CH2, and CH3) or portions thereof. An example of a             hybrid constant region IgG heavy chain molecule would be one             having an IgG1 CH1 domain with a hinge region derived from             IgG1 and the remaining carboxy-terminal portion of the             polypeptide derived from that of the CH2 and CH3 domains of             the IgG2 heavy chain;         -   ii. two light chain polypeptides covalently bound each             (individually) to a single heavy chain polypeptide (of item             [i] immediately above), wherein such covalent bond consists             of at least one cysteine-to-cysteine interchain disulfide             bond between a single said light chain and a single said             heavy chain polypeptide, and wherein such light chain             polypeptides are of the kappa or the lambda type of light             chain immunoglobulin molecules, each of which comprising,             consisting, or consisting essentially of at least one             variable domain (VL) and at least one light chain constant             domain;     -   b. The antibodies may have an apparent molecular mass (as         determined by SDS-PAGE analysis using 8%-12% polyacrylamide gels         under non-reducing conditions) greater than about 100,000         daltons and less than about 250,000 daltons, greater than about         120,000 and less than about 180,000 daltons, or about 140,000 to         165,000 daltons, in apparent molecular mass;     -   c. The antibodies may have heavy chain constant regions with         amino acid compositions that are at least 85%, 90%, 95%, 96%,         97%, 98%, or 99% identical to the heavy chain constant regions         of naturally occurring human IgG isotype molecules of class 1         (IgG1), 2 (IgG2), 3 (IgG3), or 4 (IgG4), wherein such identity         is determined for each amino acid of the antibodies compared to         each corresponding position naturally occurring in human IgG         heavy chains of any isotype, as found by genetic sequencing or         as reported in the relevant literature or as found in any         therapeutic IgG antibody used to treat human patients, wherein         such identity comparison allows sufficient sequence gap-lengths         and a sufficient quantity of gaps so as to maximize identity         between compared polypeptides. The composition of said naturally         occurring human antibody molecules includes any and all         allotypic variants (see, e.g., Jefferis R, Lefranc M P. Human         immunoglobulin allotypes: possible implications for         immunogenicity (2009 July-August) MAbs 1:332; PubMed ID:         20073133);     -   d. The antibodies may have light chain constant regions with         amino acid compositions that at least 85%, 90%, 95%, 96%, 97%,         98%, or 99% identical to the light chain constant regions of         naturally occurring human kappa or lambda type molecules,         wherein such identity is determined for each amino acid of the         antibodies compared to each corresponding position naturally         occurring in human light chains as found by genetic sequencing         or as reported in the relevant literature or as found in any         therapeutic antibody used to treat human patients, wherein such         identity comparison allows sufficient sequence gap-lengths and a         sufficient quantity of gaps so as to maximize identity between         compared polypeptides. The composition of said naturally         occurring human antibody molecules includes any and all possible         allotypic variants (see, e.g., Jefferis R, Lefranc M P. Human         immunoglobulin allotypes: possible implications for         immunogenicity (2009 July-August) MAbs 1:332; PubMed ID:         20073133);     -   e. The antibodies may comprise, consist, or consist essentially         of heavy chain variable (VH) and light chain variable (VL)         domains derived from a mammalian source (e.g., human, primate,         rabbit, ruminant, mouse or other rodent). In cases where the VH         or the VL coding source is not human, the antibody may be either         chimeric (due to the presence of human constant regions) or         humanized (due to the grafting of non-human amino acid sequences         onto a human framework variable region);     -   f. In one embodiment, the antibodies are not conjugated to any         of the following: (1) a cytotoxin (e.g., vincristine), (2) a         radioactive substance (e.g., ¹¹¹indium), (3) an imaging agent         (e.g., fluorescein), (4) a small molecule therapeutic drug         (e.g., bleomycin), (5) a therapeutic non-antibody polypeptide         (e.g., interferon-gamma), (6) an enzyme (e.g., a         peroxidase), (7) a vaccine-substance (e.g., a viral         polypeptide), or (8) a polyethylene glycol molecule (e.g., PEG).     -   g. In one embodiment, the antibodies are conjugated to any of         the following: (1) a cytotoxin (e.g., vincristine), (2) a         radioactive substance (e.g., ¹¹¹indium), (3) an imaging agent         (e.g., fluorescein), (4) a small molecule therapeutic drug         (e.g., bleomycin), (5) a therapeutic non-antibody polypeptide         (e.g., interferon-gamma), (6) an enzyme (e.g., a         peroxidase), (7) a vaccine-substance (e.g., a viral         polypeptide), or (8) a polyethylene glycol molecule (e.g., PEG).

The antibodies in the composition and method embodiments may exhibit any or all of the following structure-function correlates:

-   -   a. The antibodies may comprise, consist, or consist essentially         of two CD32 binding domains that derive from the variable (Fab)         regions formed by each of the two heavy-light chain pairs, and         because of this divalent structure have the capacity to bind         either one or two antigen epitopes;     -   b. The Fc region of the antibodies is either reduced in its         ability, or completely lacking the ability, to bind human CD16,         CD32, or CD64 IgG receptors, wherein such reduced IgG receptor         binding activity is the result of either (1) fusion (e.g.,         hybridization) of two or more IgG-Fc-region polypeptide         sequences, (2) enzymatic modification of Fc-region carbohydrate         molecules (e.g., modification or removal of a carbohydrate         molecule from the asparagine residue located at position 297 in         the EU index of Kabat), or (3) engineered amino acid mutations         at one or more positions in the constant region of the IgG heavy         chain, wherein such engineered mutations reduce or eliminate         Fc-dependent binding to the following types of classical human         IgG receptors: CD16, CD32, and CD64;     -   c. The antibodies, when bound to human CD32, form stable immune         complexes that inhibit the capacity of the Fc region of other         IgG antibodies to cause said CD32 molecules to directly induce         inflammatory cellular reactions, wherein such other IgG         antibodies are either: (1) bound in a Fab-dependent manner to at         least one antigen molecule, or (2) clustered into an assembly of         at least two such IgG molecules, or (3) localized to a surface         in such a manner so as to restrict aqueous diffusion of said IgG         molecule.

Nucleic Acids, Vectors, and Host Cells

The invention also provides a synthetic or recombinant nucleic acid sequence encoding any of the antibodies described herein. Such nucleic acid is, for instance, isolated from a B-cell that is capable of producing an antibody described herein. Such nucleic acids encode the heavy and light chain sequences set forth herein. Alternatively, such nucleic acids encode heavy and light chain sequences comprising the heavy and light chain CDRs, respectively, set forth herein. In some embodiments, the nucleic acids will encode functional parts of the antibodies described herein. Due to the degeneracy of the nucleic acid code, multiple nucleic acids will encode the same amino acid and all are encompassed herein. Certain encompassed nucleic acids are described in Tables 1-5.

In some aspects, the invention comprises a vector comprising a nucleic acid molecule as described herein. In some embodiments, the invention comprises a host cell comprising a nucleic acid molecule as described herein.

In some aspects, the invention comprises a nucleic acid molecule encoding at least one antibody disclosed herein.

Methods of Making Antibodies

In one embodiment, a method of making an effector-deficient anti-CD32a antibody is provided. In one aspect the method comprises culturing a host cell comprising a nucleic acid encoding an effector-deficient anti-CD32a antibody and isolating a secreted antibody. The nucleic acid encoding the effector-deficient anti-CD32a antibody may be any nucleic acid described in Tables 1-5 or fragments or variants thereof.

In one embodiment, a host cell expressing an effector-deficient anti-CD32a antibody is encompassed. The host cell may be a mammalian cell. Non-limiting examples include host cells derived from a human individual, rodent, rabbit, llama, pig, cow, goat, horse, ape, or gorilla. In one embodiment, said host cell comprises a human cell, a murine cell, a rabbit cell and/or a llama cell.

In one embodiment, a host cell may comprise Chinese hamster ovary (CHO) cell line, 293(T) cells, COS cells, NSO cells and other cell lines known in the art and comprise nucleic acid sequences encoding the antibody described herein. Host cells may be adapted to commercial antibody production (“producer cell”). Proliferation of said producer cell results in a producer cell line capable of producing effector-deficient anti-CD32a antibodies. A producer cell line may be suitable for producing compounds for use in humans. Hence, said producer cell line may be free of pathogenic agents such as pathogenic micro-organisms.

Further provided is a method for producing antibodies which are capable of specifically binding CD32a, wherein the antibody prevents the activation of CD32a by immobilized IgG or prevents activation of CD32 by IgG immune complexes, the method comprising: producing an antibody-producing cell capable of producing said effector-deficient antibodies and obtaining antibodies produced by said antibody producing cell.

An isolated or recombinant antibody, as well as an isolated or recombinant host cell, obtainable by one of the methods provided herein, or a functional equivalent thereof, is also provided.

In one embodiment, the antibodies were produced by obtaining nucleic acid molecules coding for the variable region of light chain and heavy chains of anti-CD32a antibodies (IV.3, AT-10, and MDE-8). For example, the antibodies may be obtained: 1) from hybridoma cell lines by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) using ribonucleic acid (RNA) isolated from these cell lines and oligo primers directed to the 5′ leader coding sequence and 5′ constant chain coding sequence, or 2) by producing synthetic molecules (by commercially available means) containing the known nucleic acid sequences of variable regions of light chain and heavy chains of anti-CD32a antibodies.

In one embodiment, nucleic acid molecules coding for humanized variable regions of light chains and heavy chains of anti-CD32a antibodies were obtained by producing synthetic molecules (by commercially available means) containing the known nucleic acid sequences with the modification described herein.

In one embodiment, nucleic acid molecules coding for the variable region of light chains and heavy chains of anti-CD32a antibodies (IV.3, AT-10, and MDE-8) were cloned into commercially available plasmid vectors, pFUSE, that contain the respective nucleic acid sequences coding for the light chain constant region (immunoglobulin kappa), and the heavy chain constant regions (human IgG1 or human IgG2).

In one embodiment, effector-deficient anti-CD32a antibodies were produced by creating nucleic acid mutations by site-directed mutagenesis on the heavy chain constant regions coding sequences of pFUSE plasmids.

In one embodiment, anti-CD32a antibodies were produced by transfecting human embryonic kidney cells (e.g. Expi293 cells) with pFUSE plasmid vectors containing nucleic acid molecules coding for variable regions as well as constant regions of light and heavy antibody chains. In some aspects, the nucleic acid molecules coded for chimeric, humanized, or human anti-CD32a mAbs, in IgG1 or IgG2 isotype subclass, in native (effector-competent) or mutated (effector-deficient) format.

In one embodiment, anti-CD32a antibodies secreted by transfected cells were purified from culture media by Protein G column purification and dialized in buffered saline prior to use.

Pharmaceutical Compositions

The invention comprises a pharmaceutical composition comprising at least one effector-deficient anti-CD32a antibody as described herein and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises an additional active agent.

In certain embodiments, the pharmaceutical composition will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format and desired dosage. See, for example, Remington's Pharmaceutical Sciences, 18th Edition, A. R. Gennaro, ed., Mack Publishing Company (1995). In certain embodiments, such compositions may influence the physical state, stability, rate of in vivo release and rate of in vivo clearance of the antibodies of the invention.

In certain embodiments, the excipient in the pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, in certain embodiments, a suitable excipient can be water for injection, physiological saline solution or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. In some embodiments, the saline comprises isotonic phosphate-buffered saline. In certain embodiments, neutral buffered saline or saline mixed with serum albumin are further exemplary excipients. In certain embodiments, pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute therefore. In certain embodiments, a composition comprising an effector-deficient antibody as described herein, with or without at least one additional therapeutic agents, can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents (Remington's Pharmaceutical Sciences, supra) in the form of a lyophilized cake or an aqueous solution. Further, in certain embodiments, a composition comprising an effector-deficient antibody as described herein, with or without at least one additional therapeutic agents, can be formulated as a lyophilizate using appropriate excipients such as sucrose.

The antibodies/compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.

CD32a-Mediated Mediated Diseases and Disorders

CD32a-mediated diseases and disorders include heparin-induced thrombocytopenia (HIT), immune thrombocytopenic purpura (ITP), antiphospholipid syndrome (APS), thrombosis associated with autoimmunity or with certain drugs (e.g., heparin) and antibody therapies (e.g., anti-VEGF or anti-CD40L immunotherapies), transfusion or organ transplantation reactions, certain viral infections, rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, inflammatory bowel disease, osteoarthritis, systemic lupus erythematous (SLE), asthma, allergic rhinitis, lupus nephritis, antibody-mediated anemias, anaphylaxis and airway inflammation. See, e.g., Gillis C et al. Contribution of Human FcgammaRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies (2014 May 30) Front Immunol 5:254; PubMed ID: 24910634; Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models (2012 Jun. 14) Blood, 119(24):5640-9, PubMed ID: 22535666; and Hogarth P M and Pietersz G A, Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond (2012 Mar. 30) Nat Rev Drug Discov 11(4):311-31, PubMed ID: 22460124.

In one embodiment, the CD32a-mediated disease or disorder is thrombocytopenia. Thrombocytopenia is characterized by a drop in circulating platelets. In one embodiment, thrombocytopenia is defined as a platelet count less than the lower limit of normal (usually taken as 150×10⁹/L). In other embodiments, thrombocytopenia is defined as a fall in the number of circulating platelets. For example, a fall in the platelet count of 30-50% or more, following administration of heparin, may be a symptom of heparin-induced thrombocytopenia, even if the platelet count does not fall below 150×10⁹/L. (Warkentin T E. Clinical presentation of heparin-induced thrombocytopenia (October 1998) Semin Hematol 35(4 Suppl 5):9-16; discussion 35-6; PubMed ID: 9855179). The platelet count is typically measured by electronic counting methods, and usually as part of a Complete Blood Count (CBC). Methods for treating thrombocytopenia with any one of or a combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

In another embodiment, the CD32a-mediated disease or disorder is IgG-mediated thrombosis. In one embodiment, IgG-mediated thrombosis is thrombosis caused by IgG immune complexes or by immobilzed IgG (see, e.g., Reilly M P et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001 Oct. 15; 98(8):2442-7. PubMed ID: 11588041; and also Taylor S M et al. Thrombosis and shock induced by activating antiplatelet antibodies in human FcgammaRIIA transgenic mice: the interplay among antibody, spleen, and Fc receptor. Blood. 2000 Dec. 15; 96(13):4254-60. PubMed ID: 11110699, respectively). Methods for treating IgG-mediated thrombosis with any one of or a combination of the effector-deficient antibodies described herein are encompassed. A method for treating IgG-mediated thrombosis comprising administering one or a combination of an effector-deficient antibody as described herein, alone or in combination with other therapies, wherein IgG-thrombosis is any thrombosis caused by IgG immune complexes or by immboilized IgG, is encompassed.

In some aspects, the CD32a-mediated disease or disorder is caused, at least in part, by activation of CD32a on or in cells (Hogarth P M et al. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond (30 Mar. 2012) Nat Rev Drug Discov 11:311; PubMed ID: 22460124), including platelets, monocytes, neutrophils, basophils, eosinophils, macrophages, dendritic cells (Boruchov A M et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions (October 2005) J Clin Invest 115:2914; PubMed ID: 16167082), mast cells, and dermal microvascular endothelial cells (Groger M et al. Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro (15 Feb. 1996) J Immunol 156:1549; PubMed ID: 8568259). In some other aspects, the CD32a-mediated disease or disorder is caused, at least in part, by activation of CD32a on malignant cells, e.g., Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, anaplastic large cell lymphoma, cutaneous T-cell lymphomas, nodular small cleaved-cell lymphomas, lymphocytic lymphomas, peripheral T-cell lymphomas, Lennert's lymphomas, immunoblastic lymphomas, T-cell leukemias/lymphomas, adult T-cell leukemia, follicular lymphomas, diffuse large cell lymphomas of B lineage, angioimmunoblastic lymphadenopathy (AILD)-like T-cell lymphoma, HIV-associated body cavity based lymphomas, Embryonal carcinomas, undifferentiated carcinomas of the rhino-pharynx, Castleman's disease, Kaposi sarcoma and other B-cell lymphomas. Methods for treating a disease or disorder characterized by activation of CD32a with any one of or a combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

In one embodiment, the CD32a-mediated disease or disorder is an immune, autoimmune, allergic, or inflammatory disease or disorder. The immune, autoimmune, allergic, or inflammatory disorder may be rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, inflammatory bowel disease, including Crohn's disease and ulcerative colitis, antiphospholipid syndrome (APS), atopic dermatitis, chronic inflammatory pulmonary disease, osteoarthritis, systemic lupus erythematous (SLE), lupus nephritis, systemic scelrosis, Graves' disease, Hashimoto's thyroiditis, Wegner's granulomatosis, Omen's syndrome, chronic renal failure, idiopathic thrombocytopenic purpura, insulin-dependent diabetes mellitus, acute infectious mononucleosis, HIV, herpes virus-associated diseases, multiple sclerosis, hemolytic anemia, thyroiditis, stiff man syndrome, pemphigus vulgaris, and myasthenia gravis, antibody-mediated arthritis, or antibody-induced anemias or cytopenias. Methods for treating an immune, autoimmune, allergic, or inflammatory disease or disorder with any one of or a combination of the effector-deficient antibodies described herein are encompassed. Methods for treating rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, inflammatory bowel disease, including Crohn's disease and ulcerative colitis, antiphospholipid syndrome (APS), atopic dermatitis, chronic inflammatory pulmonary disease, osteoarthritis, systemic lupus erythematous (SLE), lupus nephritis, antibody-mediated arthritis, or antibody-induced anemias or cytopenias with any one of or a combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

The CD32a-mediated disease or disorder may be an immune complex-mediated disease or disorder. Immune complex-mediated diseases or disorders are characterized by localized or systemic inflammatory processes that damage cells and tissues, as in the cases, for example, of inflammation caused by IgG-induced release of Tumor Necrosis Factor alpha (TNF-alpha, an inflammatory cytokine) from monocytes in RA (Mathsson L et al. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells (2006) Arthritis Res Ther 8:R64; PubMed ID: 16569263), or of kidney damage caused by polymorphonuclear cells (neutrophils, basophils, eosinophils) in SLE and glomerulonephritis (Suzuki Y et al. Pre-existing glomerular immune complexes induce polymorphonuclear cell recruitment through an Fc receptor-dependent respiratory burst: potential role in the perpetuation of immune nephritis (2003 Mar. 15) J Immunol 170:3243; PubMed ID: 12626583; Rovin B H. The chemokine network in systemic lupus erythematous nephritis (2008 Jan. 1) Front Biosci 13:904; PubMed ID: 17981599). Immune complex-mediated diseases or disorders include numerous other acute and chronic conditions (Gillis C et al. Contribution of Human FcgammaRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies (2014 May 30) Front Immunol 5:254; PubMed ID: 24910634). Methods for treating an immune complex-mediated disease or disorder with any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

Diseases or disorders known to be associated with immune complex formation include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), heparin-induced thrombocytopenia (HIT), lupus nephritis, and APS. Methods for treating rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), heparin-induced thrombocytopenia (HIT), lupus nephritis, and APS with any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

The types of immune complexes associated with such diseases or disorders include circulating IgG immune complexes, deposited IgG immune complexes, and immobilized IgG immune complexes. Methods for treating any disease or disorder characterized by circulating IgG immune complexes, deposited IgG immune complexes, or immobilized IgG immune complexes with any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

In one embodiment, a disease or disorder characterized by circulating IgG immune complexes, deposited IgG immune complexes, or immobilized IgG immune complexes includes RA and SLE characterized by circulating IgG immune complexes. See, e.g., Zhao X et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis (2008) Arthritis Res Ther 10:R94; PubMed ID: 18710572; Ohyama K et al. Immune complexome analysis of serum and its application in screening for immune complex antigens in rheumatoid arthritis (2011 June) Clin Chem 57:905; PubMed ID: 21482748; Soares N M et al. An improved anti-C3/IgG ELISA for quantification of soluble immune complexes (1 Mar. 2001) J Immunol Methods 249:199; PubMed ID: 11226477; and Huber C et al. C3-containing serum immune complexes in patients with systemic lupus erythematosus: correlation to disease activity and comparison with other rheumatic diseases (1989) Rheumatol Int 9:59; PubMed ID: 2814209). Methods for treating RA and SLE, wherein the RA or SLE is characterized by circulating IgG immune complexes with any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

In one embodiment, a disease or disorder characterized by circulating IgG immune complexes, deposited IgG immune complexes, or immobilized IgG immune complexes includes RA, SLE, and APS characterized by IgG immune complexes deposited on circulating cells or particles or in tissues. See, e.g., Zhao X et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis (2008) Arthritis Res Ther 10:R94; PubMed ID: 18710572; Nielsen C T et al. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation (April 2012) Arthritis Rheum 64:1227; PubMed ID: 22238051; and de Groot P G et al. The significance of autoantibodies against beta-2 glycoprotein I (Jul. 12, 2012) Blood 120:266; PubMed ID: 22553312). Methods for treating RA, SLE, and APS, wherein the RA, SLE, or APS is characterized by IgG immune complexes deposited on circulating cells or particles or in tissues with any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

In one embodiment, a disease or disorder characterized by circulating IgG immune complexes, deposited IgG immune complexes, or immobilized IgG immune complexes includes RA, SLE, HIT, and APS, wherein the RA, SLE, HIT, or APS is characterized by soluble or immobilized immune complexes. See, e.g., Ohyama K et al. Immune complexome analysis of serum and its application in screening for immune complex antigens in rheumatoid arthritis (2011 June) Clin Chem 57:905; PubMed ID: 21482748; Ronnelid J et al. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE (January 2003) Ann Rheum Dis 62:37; PubMed ID: 12480667; Cines D B et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly (February 2007) J Clin Apher 22:31; PubMed ID: 17285619; and de Groot P G et al. The significance of autoantibodies against beta-2 glycoprotein I (Jul. 12, 2012) Blood 120:266; PubMed ID: 22553312. Methods for treating RA, SLE, HIT, or APS, wherein the RA, SLE, HIT, or APS is characterized by soluble or immobilized immune complexes with any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

Importantly, more than one type of the above-mentioned immune complexes may be present simultaneously or at differing times in these and other immune complex diseases and disorders. Even in this scenario, the effector-deficient antibodies described herein may be administered to treat one or all of the diseases and disorders.

In one embodiment, methods of treating diseases or disorders characterized by antibodies that bind PF4 complexes comprising administering any one of or any combination of the effector-deficient anti-CD32a monoclonal antibodies are encompassed. Antibodies to human platelet factor 4 (PF4) complexes have been identified in RA, APS, SLE, and HIT. See, e.g., Ohyama K et al. Immune complexome analysis of serum and its application in screening for immune complex antigens in rheumatoid arthritis (2011 June) Clin Chem 57:905; PubMed ID: 21482748; Sikara M P et al. Beta 2 Glycoprotein I binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome (Jan. 21, 2010) Blood 115:713; PubMed ID: 19805618; Satoh T et al. Heparin-dependent and -independent anti-platelet factor 4 autoantibodies in patients with systemic lupus erythematosus (2012 September) Rheumatology (Oxford) 51:1721 PubMed ID: 22718864; and Warkentin T E et al. HITlights: a career perspective on heparin-induced thrombocytopenia (2012 May) Am J Hematol 87:S92; PubMed ID: 22367928. Thus, in one embodiment, methods of treating RA, APS, SLE, and HIT, wherein the RA, APS, SLE, or HIT is characterized by antibodies that bind PF4 complexes, comprising administering any one of or any combination of the effector-deficient anti-CD32a monoclonal antibodies, either alone or in combination with existing therapies, are encompassed.

In HIT, anti-PF4 IgG antibodies are known to mediate thrombocytopenia and thrombosis via platelet CD32a, where therapeutic amounts of heparin (where heparin is bound to PF4 antigen) play a key role in localizing HIT immune complexes to the platelet surface. See, e.g., Newman P M et al. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation (1 Jul. 2000) Blood 96:182; PubMed ID: 10891449.

In one embodiment, the immune complex-mediated disease is an anti-therapeutic-antibody (ATA) response caused by administration of a non-anti-CD32a antibody or antigen-binding fragment thereof. The non-anti-CD32a antibody may be infliximab, adalimumab, the IgG-Fc-fusion therapeutic, etanercept, certolizumab pegol, golimumab, etanercept, ustekinumab, bevacizumab, omalizumab, belimumab, or tabalumab. In these method embodiments, the effector deficient anti-CD32a antibody may be administered prior to, concurrently with, or following the non-anti-CD32a monoclonal antibody.

In one embodiment, the immune complex-mediated disease or disorder occurs in a patient being treated with a non-anti-CD32a monoclonal antibody for the treatment of RA, SLE, HIT, lupus nephritis, or antiphospholipid syndrome (APS). Methods for treating RA, SLE, HIT, lupus nephritis, or antiphospholipid syndrome (APS), wherein the patient is or has received a non-anti-CD32a monoclonal antibody, with any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

In other embodiments, the disease or disorder is a hemostatic disorder. The hemostatic disorder may be selected from the group consisting of antibody-mediated-thrombocytopenia, immune-mediated-thrombocytopenia (ITP), heparin-induced thrombocytopenia (HIT), and heparin-induced thrombocytopenia with thrombosis (HITT). Methods for treating a hemostatic disorder comprising administering any one of or any combination of the effector-deficient antibodies described herein is encompassed. Also encompassed are methods for treating antibody-mediated-thrombocytopenia, immune-mediated-thrombocytopenia (ITP), heparin-induced thrombocytopenia (HIT), and heparin-induced thrombocytopenia with thrombosis (HITT) comprising administering any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies (e.g., anticoagulants).

Also encompassed are methods for treating hemostatic disorders caused by treatment of patients with IV-Ig comprising administering any one of or any combination of the effector-deficient antibodies described herein, where such effector-deficient antibodies are administered prior to IV-Ig, concurrently with IV-Ig, or subsequently to IV-Ig treatment. IV-Ig is useful for treating autoimmune and transplant patients, but is associated with side effects such as thrombocytopenia and acute arterial and venous thrombosis, anaphylactic shock, transitory renal failure, increased risk of infection, and leucopenia. Thrombosis has been increasingly recognized in treatment with IV-Ig (Paran D et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins (July (2005) Blood Coagul Fibrinolysis 16:313; PubMed ID: 15970713; Woodruff R K et al. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients (July 1986) Lancet 2:217; PubMed ID: 2873457). Serious thromboembolic events observed with IV-Ig use include deep venous thrombosis (DVT), myocardial infarction (MI), pulmonary embolism (PE), central retinal vein occlusion, and cerebrovascular accidents (CVA). Pollreisz and colleagues showed that IVIg can induce activation, aggregation, degranulation, and inflammatory cytokine release from platelets in a CD32-dependent manner, and this IVIg-induced CD32-dependent platelet activation was completely blocked by AT-10, demonstrating that platelet CD32 was both necessary and sufficient for IVIg-induced prothrombotic activity (Pollreisz A et al. Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro (September 2008) Br J Dermatol 159:578; PubMed PMID: 18565176).

In still other embodiments, the CD32a-mediated disease or disorder is an allergic disorder. The allergic disorder may be selected from the group consisting of ashtma, contact dermatitis, allergic rhinitis, anaphylaxis, and allergic reactions. Methods for treating allergic disorder comprising administering any one of or any combination of the effector-deficient antibodies described herein are encompassed. Likewise, methods for treating asthma, contact dermatitis, allergic rhinitis, anaphylaxis, and allergic reactions comprising administering any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

The presence of both the CD32 IgG receptor and the IgE receptor (Hasegawa S et al. Functional expression of the high affinity receptor for IgE (FcepsilonRl) in human platelets and its' [sic] intracellular expression in human megakaryocytes (April 1999) Blood 93:2543; PubMed ID: 10194433) on the surface of human platelets indicates a vital link between platelets and allergy, which is particularly evident in pulmonary inflammation, as occurs in asthma and chronic lung disease (Page C et al. Platelets and allergic inflammation (July 2014) Clin Exp Allergy 44:901; PubMed ID: 24708345). The link between CD32 and IgE has similarly been recognized for immature B-lymphocytes, where IV.3 or AT-10 blockade of CD32 on human tonsillar B-cells was shown to suppress both inducible IgG and inducible IgE synthesis (Horejs-Hoeck J et al. Inhibition of immunoglobulin E synthesis through Fc gammaRII (CD32) by a mechanism independent of B-cell receptor co-cross-linking (July 2005) Immunology 115:407; PubMed ID: 15946258). A mechanistic explanation for CD32/IgE synergy may have recently been identified in the capacity of IV.3 and AT-10 to induce an anti-inflammatory state in CD32a-bearing cells (Ben Mkaddem S et al. Shifting Fc[gamma]RIIA-ITAM from activation to inhibitory configuration ameliorates arthritis (September 2014) J Clin Invest 124:3945; PubMed PMID: 25061875). The role of CD32a in allergy may also be linked to disorders of hemostasis (Potaczek D P. Links between allergy and cardiovascular or hemostatic system (January 2014) Int J Cardiol 170:278; PubMed ID: 24315352).

In one embodiment, effector-deficient anti-CD32a monoclonal antibodies are used to suppress inflammation driven by reactions in cells displaying CD32a, where such CD32a binds IgG molecules that are immobilized on a surface, such as that of platelets or red blood cells. For example, immobilized IgG binds and activates platelet CD32a, leading to adhesion and granule secretion, and this process has been shown to be blocked by IV.3 (Haimovich B et al. The FcgammaRII receptor triggers pp125FAK phosphorylation in platelets (July 1996) J Biol Chem 271:16332; PubMed ID: 8663117). Additionally, IgG-coated red blood cells are phagocytosed via CD32a, and this activity is inhibited by IV.3 (Wiener E et al. Role of Fc gamma RIIa (CD32) in IgG anti-RhD-mediated red cell phagocytosis in vitro (September 1996) Transfus Med 6:235; PubMed ID: 8885153). Additionally, IgG-coated cells are cleared in a CD32a-dependent manner in patients with SLE, where such mechanism is inhibited by IV.3 (Seres T et al. Correlation of Fc gamma receptor expression of monocytes with clearance function by macrophages in systemic lupus erythematosus (September 1998) Scand J Immunol 48:307; PubMed ID: 9743218).

In one embodiment, effector-deficient anti-CD32a monoclonal antibodies are used to suppress inflammation driven by reactions in cells displaying CD32a, where such CD32a interacts with IgG molecules bound to self antigens, such as von Willebrand Factor (vWF), and localize to the CD32a-positive cell, leading to inflammatory activation that is known to be inhibited by IV.3 (for example, see Hoylaerts M F et al. Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc gamma RII receptor-mediated platelet activation (April 1998) Blood 91:2810; PubMed ID: 9531591). Thus, methods for suppressing inflammation comprising administering one or more effector-deficient anti-CD32a monoclonal antibodies, thereby suppressing inflammation, are encompassed.

In one embodiment, effector-deficient anti-CD32a monoclonal antibodies are used to suppress inflammation driven by infectious viruses. For example, IV.3 is known to inhibit dengue virus infection of human mast cells (Brown M G et al. A dominant role for FcgammaRII in antibody-enhanced dengue virus infection of human mast cells and associated CCL5 release (December 2006) J Leukoc Biol 80:1242; PubMed ID: 16940332). Thus, methods for suppressing inflammation comprising administering one or more effector-deficient anti-CD32a monoclonal antibodies, wherein the inflammation is mediated by infectious viruses, thereby suppressing inflammation, are encompassed.

In one embodiment, effector-deficient anti-CD32a monoclonal antibodies are used to suppress inflammation driven by infectious microbes. For example, staphylococcus aureus can cause infective endocarditis, inducing platelet-driven CD32a inflammatory reactivity, which is inhibited by IV.3 (Fitzgerald J R et al. Fibronectin-binding proteins of Staphylococcus aureus, Streptococcus sanguinis, Streptococcus gordonii, Streptococcus oralis, and Streptococcus pneumoniae mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor (January 2006) Mol Microbiol 59:212; PubMed ID: 16359330; Arman M et al. Amplification of bacteria-induced platelet activation is triggered by Fc[gamma]RIIA, integrin [alpha]IIb[beta]3, and platelet factor 4 (May 2014) Blood 123:3166; PubMed ID: 24642751). Similarly, systemic inflammation, sepsis-associated vascular leakage, platelet activation, and coagulation dysfunction in gram-positive sepsis can be CD32a-mediated, and these inflammatory processes are blocked by IV.3 (Sun D et al. Bacillus anthracis peptidoglycan activates human platelets through Fc[gamma]RII and complement (July 2013) Blood 122:571; PubMed ID: 23733338). Thus, methods for suppressing inflammation comprising administering one or more effector-deficient anti-CD32a monoclonal antibodies, wherein the inflammation is mediated by infectious microbes, thereby suppressing inflammation, are encompassed.

In one embodiment, effector-deficient anti-CD32a monoclonal antibodies are administered as treatment to patients along with or as a replacement for IV-Ig. Intravenous immunoglobulin (IgG), or “IV-Ig”, is approved by the FDA for treatment of various autoimmune or inflammatory diseases, including Primary Humoral Immunodeficiency, Multifocal Motor Neuropathy, B-cell Chronic Lymphocytic Leukemia, Immune Thrombocytopenic Purpura, Kawasaki syndrome, Chronic Inflammatory Demyelinating Polyneuropathy. IVIg is also used to treat neonatal alloimmune thrombocytopenia, HIV-associated thrombocytopenia, autoimmune neutropenia, autoimmune hemolytic anemia, interstitial pneumonia or cytomegalovirus infection in bone marrow transplant patients, bullous pemphigoid, epidermolysis bullosa acquisita, mucous-membrane pemphigoid, necrotizing fasciitis, pemphigus foliaceus, pemphigus vulgaris, toxic epidermal necrolysis or Stevens-Johnson syndrome, birdshot retinopathy, Guillain-Barré syndrome, Lambert-Eaton myasthenic syndrome, myasthenia gravis, opsoclonus-myoclonus, polyradiculoneuropathy, refractory dermatomyositis, refractory polymyositis, relapsing-remitting multiple sclerosis. Effector-deficient anti-CD32a monoclonal antibodies may be used to treat these conditons.

In each of the method embodiments, the CD32a-mediated disease or disorder may be characterized by symptoms of shock. As used herein, the term “shock” includes, but is not limited to, hypersensitivity reactions of type I (i.e., mediated by IgE), type II (i.e., mediated by immobilized IgG), or type III (i.e., mediated by IgG complexes), IgG-mediated thrombotic reactions, and IgG-mediated neurologic reactions. Methods for alleviating the symptoms of shock comprising administering any one of or any combination of the effector-deficient antibodies described herein, alone or in combination with other therapies, are encompassed.

EXEMPLARY EMBODIMENTS

In one embodiment, a method for treating a CD32a-mediated disease or disorder in a human subject comprising administering a therapeutically effective amount of an effector-deficient anti-CD32a monoclonal antibody to a human subject, wherein the antibody comprises at least a portion of an Fc region and is effector-deficient, thereby treating the CD32a-mediated disease or disorder is provided.

In one embodiment, the effector-deficient antibody satisfies both the IgG Immune Complex Test and the Immobilized IgG Test, and has an Fc region that has been altered so as to reduce or eliminate Fc-binding to CD16, CD32, and/or CD64 type IgG receptors.

In any of the method embodiments described herein, the CD32a-mediated disease or disorder may be an IgG-mediated hemostatic disorder. The hemostatic disorder may be thrombosis with or without thrombocytopenia. The hemostatic disorder may be selected from the group consisting of IgG-mediated-thrombocytopenia, immune-mediated-thrombocytopenia (ITP), antiphospholipid syndrome (APS), anti-platelet-antibody disorders, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia with thrombosis (HITT), cancer-induced platelet activation, cancer-induced hypercoagulability, platelet-mediated tumor cell metastasis, and platelet-mediated cancer metastasis.

In any of the method embodiments described herein, the CD32a-mediated disease or disorder may be characterized by IgG-Fc-mediated activation of CD32a on platelets, monocytes, neutrophils, basophils, eosinophils, macrophages, dendritic cells, synovial cells, mast cells, or dermal microvascular endothelial cells.

In any of the method embodiments described herein, the CD32a-mediated disease or disorder may be an IgG-mediated immune, autoimmune, or inflammatory disease or disorder. The IgG-mediated immune, autoimmune or inflammatory disorder may be selected from the group consisting of rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, antiphospholipid syndrome (APS), osteoarthritis, systemic lupus erythematous (SLE), lupus nephritis, IgG antibody-induced anemia, and IgG-mediated cytopenia.

In any of the method embodiments described herein, the CD32a-mediated disease or disorder may be an IgG immune complex-mediated disease or disorder. The IgG immune complex-mediated disease may be an anti-therapeutic-antibody (ATA) response caused by administration of a non-anti-CD32a monoclonal antibody or fragment thereof. In any of the method embodiments described herein, the non-anti-CD32a antibody may be infliximab, adalimumab, certolizumab pegol (antibody-like), golimumab, etanercept (antibody-like), ustekinumab, omalizumab, or bevacizumab. In any of the method embodiments described herein, the effector deficient anti-CD32a antibody may be administered prior to, concurrently with, or following the non-anti-CD32a monoclonal antibody. In any of the method embodiments, alone or in combination with other methods, the IgG immune complex-mediated disease or disorder may occur in a patient being treated with a non-anti-CD32a monoclonal antibody for the treatment of rheumatoid arthritis, systemic lupus erythematosus (SLE), lupus nephritis, or inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.

In any of the method embodiments, the CD32a-mediated disease or disorder may be characterized by IgG localized on the surface of cells circulating in the blood of the human subject. The circulating cell type may be one or more of the following: platelets, erythrocytes, monocytes, neutrophils, basophils, eosinophils, B-lymphocytes, macrophages, mast cells, leukemia cells, or microbes such as viruses, bacteria, fungal, or parasitic organisms. In any of the method embodiments, the disease or disorder that is characterized by IgG localized on the surface of cells may be one or more of the following: thrombocytopenia, leukopenia, neutropenia, lymphopenia, monocytopenia, anemia, hemolytic anemia, or sepsis.

In some embodiments, a method for treating antibody-mediated allergic or hypersensitivity reactions of type I, type II, or type III in a human subject comprising: administering a therapeutically effective amount of an effector-deficient anti-CD32a monoclonal antibody to a human subject, wherein the antibody comprises at least a portion of an Fc region and is effector-deficient, thereby treating the antibody-mediated allergic or hypersensitivity reactions of type I, type II, or type III, is provided. In this and any of the method embodiments, or in any combination of method embodiments, the effector-deficient antibody satisfies both the IgG Immune Complex Test and the Immobilized IgG Test, and has an Fc region that has been altered so as to reduce or eliminate Fc-binding to CD16, CD32, and/or CD64 type IgG receptors. In any of the method embodiments, the allergic disorder may be selected from the group consisting of atopy, contact dermatitis, allergic rhinitis, systemic anaphylaxis, localized anaphylaxis as exhibited in hay fever, asthma, hives, food allergies, eczema, allergic reactions to vaccines, allergic reactions to foods, allergic reactions to insect products, allergic reactions to drugs, allergic reactions to mold spores, allergic reactions to animal hair and dander, allergic reactions to latex, blood transfusion reactions, platelet transfusion reactions, erythrocyte transfusion reactions, erythroblastosis fetalis, hemolytic anemia, serum sickness, infusion reactions, necrotizing vasculitis, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, and allergic reactions to microorganisms.

In each of the method embodiments described herein, including any combination of the various embodiments, the effector-deficient anti-CD32a antibody may be an effector-deficient MDE-8, IV.3, or AT-10 monoclonal antibody, and the monoclonal antibody may be human or humanized.

In each of the method embodiments described herein, including any combinations of the various method embodiments, the MDE-8, IV.3, and AT-10 monoclonal antibodies may comprise the six CDRs for each antibody, as described herein and in the sequence listing, or may comprise a sequence having 1 or 2 amino acid differences in the CDRs as recited herein and in the sequence listing.

An effector deficient anti-CD32a monoclonal antibody that specifically binds human CD32a, wherein the antibody comprises at least a portion of an Fc region that is effector deficient, wherein the effector-deficient antibody comprises an altered Fc region that reduces or eliminates Fc-binding to CD16, CD32, and/or CD64 type IgG receptors, as compared to a non-altered control, is provided.

DEFINITIONS

As used herein, the term “Human CD32A mice,” “CD32A mice,” “transgenic CD32A mice,” and “transgenic human CD32A mice” are used interchangeably. CD32A mice have been previously described (McKenie et al., The role of the human Fc receptor FcgammaRIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol. 1999 Apr. 1; 162(7):4311-8. PubMed ID: 10201963).

Fc receptors (FcR) are leukocyte surface glycoproteins that specifically bind the Fc portion of antibodies. The receptors for IgG, that is FcgammaR, are the most widespread and diverse, the major types being FcgammaRT (CD64), FcgammaRII (CD32) and FcgammaRIII (CD16). As used herein, the term “CD32a” is synonymous with the activating type of FcgammaRII and iterations thereof such as iterations using the Greek gamma symbol in lieu of “gamma”.

The term “antibody” refers to an intact immunoglobulin of any isotype, or a fragment thereof that can compete with the intact antibody for specific binding to the target antigen, and includes, for instance, chimeric, humanized, fully human, and bispecific antibodies. An intact antibody may comprise at least two full-length heavy chains and two full-length light chains, but in some instances can include fewer chains such as antibodies naturally occurring in camelids, which can comprise only heavy chains. Antibodies can be derived solely from a single source, or can be “chimeric,” that is, different portions of the antibody can be derived from two different antibodies. The antigen binding proteins, antibodies, or binding fragments can be produced in hybridomas, by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Unless otherwise indicated, the term “antibody” includes, in addition to antibodies comprising two full-length heavy chains and two full-length light chains, derivatives, variants, fragments, and muteins thereof. Furthermore, unless explicitly excluded, antibodies include monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof.

As used herein, “specific binding” refers to antibody binding to a predetermined antigen. Typically, the antibody binds with dissociation constant (K_(D)) of 10E7 M or less, and binds to the predetermined antigen with a K_(D) that is at least two-fold less than its K_(D) for binding to a non-specific antigen (e.g., albumin, casein) other than the predetermined antigen or a closely-related antigen.

The term “K_(assoc)” or “K_(a)”, as used herein, is intended to refer to the association rate of a particular antibody-antigen interaction, whereas the term “K_(dis)” or “K_(d),” as used herein, is intended to refer to the dissociation rate of a particular antibody-antigen interaction. The term “K_(D)”, as used herein, is intended to refer to the dissociation constant, which is obtained from the ratio of K_(d) to K_(a) (i.e., K_(d)/K_(a)) and is expressed as a molar concentration (M).

As used herein, “isotype” refers to the antibody class (e.g., IgM or IgG) that is encoded by heavy chain constant region genes.

As used herein, the terms “inhibits binding” and “blocks binding” (e.g., referring to inhibition/blocking of binding of CD32 ligand, e.g., IgG, to CD32) are used interchangeably and encompass both partial and complete inhibition/blocking. The inhibition/blocking of IgG to CD32 preferably reduces or alters the normal level or type of effector cell functions that occurs when IgG binds to CD32 without inhibition or blocking. Inhibition and blocking are also intended to include any measurable decrease in the binding affinity of IgG to CD32 when in contact with an anti-CD32 antibody as compared to the ligand not in contact with an anti-CD32 antibody, e.g., the blocking of CD32 ligands to CD32 by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%.

An “Fc” region comprises two heavy chain fragments comprising some or all of the constant “CH” domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds. The Fc region may comprise all or part of the hinge region, either with or without additional amino acids from the heavy chain constant region. In other words, the Fc region may optionally comprise one or both of CH2 and CH3.

A “Fab′ fragment” comprises one light chain and a portion of one heavy chain that contains the VH domain and the CH1 domain and also the region between the CH1 and CH2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab′ fragments to form an F(ab′)2 molecule.

The term “vector” means any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage or virus) used to transfer protein-coding information into a host cell.

As used herein, the term “thrombocytopenia” refers to a subnormal number of platelets in the circulating blood (Wintrobe M M et al. Disorders of Platelets and Hemostasis. In: Clinical Hematology, Seventh Edition, Lea & Febiger, Philadelphia, 1974). This is typically defined as a platelet count less than the lower limit of normal (usually taken as 150×109/L). It may also be characterized as a fall in the number of circulating platelets. For example, a fall in the platelet count of 30-50% or more, following administration of heparin, may be a symptom of heparin-induced thrombocytopenia, even if the platelet count does not fall below 150×109/L. (Warkentin T E. Clinical presentation of heparin-induced thrombocytopenia (October 1998) Semin Hematol 35(4 Suppl 5):9-16; discussion 35-6; PubMed ID: 9855179). The platelet count is measured by electronic counting methods, usually as part of a Complete Blood Count (CBC).

As used herein, the term “thrombosis” refers to the formation of a blood clot inside a blood vessel (venous or arterial). Typically the blood clot, or thrombus, would consist of fibrin and blood cells, including activated platelets in various proportions.

As used herein, the phrase “IgG-mediated thrombosis” refers to thrombosis where IgG antibody molecules contribute to the formation of the thrombus.

The term “patient” and “subject” are used interchangeably herein to refer to a mammal in need of administration of a therapy.

The terms “disease” and “disorder” as used herein are intended also to include medical conditions and syndromes regarded as abnormal or indicative of impaired function, as distinguished from normal health by signs, symptoms, or laboratory-based diagnostics suggesting the presence of medical diseases or disorders.

“Treating” includes both treating and preventing.

The term “identity” refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. “Percent identity” means the percent of identical residues between the amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) are preferably addressed by a particular mathematical model or computer program (i.e., an “algorithm”). Methods that can be used to calculate the identity of the aligned nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, A. M., ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al., 1988, SIAM J. Applied Math. 48:1073.

The term “chimeric antibody” is intended to refer to antibodies in which the variable region sequences are derived from one species and the constant region sequences from another. For example, an antibody in which the heavy and light chain variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody, might be described as a mouse-human chimeric antibody.

The term “humanized antibody” is intended to refer to antibodies in which CDR sequences derived from antibodies from various mammalian species, such as a mouse, have been grafted onto human germline variable framework sequences. Additional framework region amino acid modifications may be introduced.

The term “effector function” refers to the functional ability of the Fc or constant region of the antibody to bind proteins and/or cells of the immune system and platelets. Typical effector functions of IgG antibodies include the ability to bind complement protein (e.g., C1q), the neonatal receptor (FcRn), or an IgG Fc receptor (FcgammaR) (e.g., Fcgamma RI, Fcgamma MI, Fcgamma RIII). The effects of being able to bind one or more of the foregoing molecules include, but are not limited to antigen-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), phagocytosis, opsonization, and effector cell modulation. Abrogation or decrease of effector function may refer to abrogation or decrease in one or more of the biochemical or cellular activities induced at least in part by binding of Fc to its receptors or to a complement protein or an effector cell, while maintaining the antigen-binding activity of the variable region of the antibody.

As used herein, an “effector-deficient” antibody is defined as an antibody having an Fc region that has been altered so as to reduce or eliminate Fc-binding to CD16, CD32, and/or CD64 type IgG receptors.

The term “antigen” refers to any natural or synthetic substance that could bind specifically to an antibody.

The term “specific binding” refers to antibody binding to a predetermined antigen. Typically, the antibody binds with an affinity equilibrium constant stronger than 10⁻⁷ M, and binds to the predetermined antigen with at least two-fold stronger binding to a non-specific antigen.

As used herein, the term “immune complex” refers to the molecular structures consisting of one or more antibody molecules specifically bound to one or more antigen molecules.

The term “epitope” refers to a protein determinant capable of specific binding to, or specific binding by, an antibody.

EXAMPLES Example 1 Effector-Deficient Monoclonal Antibody MDE-8

The inventors have demonstrated that native human MDE-8 mAbs cause infusion reactions in mice transgenic for its human antigen (i.e., CD32A). These mice are referred to herein as “CD32A mice.” Observable signs of IgG-mediated infusion reactions in CD32A mice include hypothermia, rapid or shallow breathing, hunched posture, and locomotor dysfunction; observable signs of severe infusion reactions also include immobilization, convulsion, apparent loss of consciousness, and (infrequently) fatality.

Altering the effector domain (i.e., Fc domain) of the MDE-8 mAb to an effector-deficient IgG format eliminated infusion reactions when administered to CD32A mice.

Moreover, when effector-deficient MDE-8 mAbs were provided prior to challenge with immune complexes, the effector-deficient MDE-8 mAbs prevented immune complex-induced infusion reactions, as well as thrombocytopenia, thrombosis, and shock.

Thus, effector-deficient monoclonal MDE-8 antibodies may be used in place of native MDE-8 antibodies to treat any CD32a mediated disease or disorder. The reasons include that the effector-deficient MDE-8 antibodies will not elicit infusion reactions as observed with native MDE-8. Moreover, when administered prophylactically or therapeutically, effector-deficient MDE-8 antibodies may be used to treat and/or prevent any disease or disorder caused by IgG immune complexes.

Materials and Methods

Effector-competent and effector-deficient variants of MDE-8 mAbs (in both IgG1 and IgG2 formats) were injected intravenously (tail vein) into CD32A mice. Two effector-deficient variants of MDE-8 were assessed in this study; E269R and N297A. CD32A mice have been previously described in McKenie et al., 1999 Apr. 1, J Immunol, 162(7):4311-8, PubMed ID: 10201963. After MDE-8 mAb injection (100 micrograms), animals were monitored for 30 minutes for assessment of infusion reactions. Blood was collected retro-orbitally before and 30 minutes after MDE-8 mAb injection. Platelets were counted by flow cytometry from this collected blood. After 3 hours, some animals were injected intravenously with a 200 micro-liter bolus of immune complexes (ICs) consisting of 150 micro-grams mouse monoclonal anti-human CD40L antibody (clone M90, a murine IgG1 mAb purified by Protein G chromatography from ATCC HB-12055 hybridoma-conditioned media) in balanced stoichiometry with its antigen, CD40L trimer (50 micro-grams) (Peprotech #310-02). Thirty minutes after IC injection, platelets were again counted. Animals were then immediately sacrificed (i.e., 30 minutes after M90+CD40L IC injection), and lungs were harvested, processed for H&E staining, and examined microscopically for the presence of thrombi.

Results Effector-Deficient MDE-8 mAbs do not Cause Infusion Reactions that are Seen with Effector Competent MDE-8 Antibodies

When injected intravenously into CD32A mice, native human MDE-8 IgG1 antibodies cause infusion reactions characterized by hypothermia, as measured by core body temperature (FIG. 1; diamonds). Mice injected with native human MDE-8 IgG1 antibodies also showed signs of severe infusion reactions, including apparent loss of consciousness (data not shown). Mouse IgG receptors have reduced binding to human IgG2 (See, e.g., Overdijk et al., Crosstalk between human IgG isotypes and murine effector cells, 2012 Oct. 1, J Immunol, 189(7): 3430-8, PubMed ID: 22956577), which is consistent with the failure of native anti-human MDE-8 antibodies in IgG2 format to cause hypothermia (FIG. 1; squares). Importantly, two representative effector-deficient human MDE-8 mAbs (in both IgG1 and IgG2 formats) (antibodies comprising the amino acids of SEQ ID NO: 69 together with SEQ ID NO: 65 or SEQ ID NO: 67) did not cause infusion reactions as observed with native human MDE-8 IgG1 antibodies (FIG. 1; triangles and X's). The failure of the IgG2 effector-competent mAb to cause hypothermia (as may be expected), even though it did cause thrombocytopenia, may be surprising to one skilled in the art. This surprising finding also makes clear that lack of hyperthermia does not indicate that the mAb is safe. The effector-deficient results provided in this experiment demonstrate that the effector-deficient antibodies described herein solve the previously unrecognized safety problem of thrombocytopenia.

It was next observed that severe thrombocytopenia followed intravenous injection of native human MDE-8 mAbs into CD32A transgenic mice in both IgG1 and IgG2 formats (FIG. 2, columns 1 and 2). In contrast, two representative effector-deficient human MDE-8 mAbs (antibodies comprising the amino acids of SEQ ID NO: 69 together with SEQ ID NO: 65 or SEQ ID NO: 67) did not induce thrombocytopenia when injected into CD32A mice (FIG. 2, columns 3 and 4). The small reduction in circulating platelet numbers seen in FIG. 2 columns 3 and 4 is typical and caused by repeated blood draws.

These experiments demonstrate that thrombocytopenia is independent of hypothermia, and that a drop in platelet count is a more sensitive indicator of infusion reaction than temperature drop, since MDE-8 in IgG2 format failed to cause hypothermia (see FIG. 1) yet largely depleted circulating platelets (FIG. 2).

Flow cytometric analysis of whole blood from CD32A transgenic mice before (FIG. 3A) and after (FIG. 3B) intravenous injection of native human MDE-8 mAbs in human IgG1 format showed severe platelet depletion (FIG. 3B). (Fluorescent beads [1 micro-meter] were included to control for blood volume [gate P5]; the upper right quadrant includes red blood cells and white blood cells [gate P4].)

Importantly, when native human MDE-8 IgG1 mAbs were made effector-deficient (antibodies comprising the amino acids of SEQ ID NO: 69 together with SEQ ID NO: 65), they failed to clear circulating platelets (compare FIG. 3C [before injection] and FIG. 3D [after injection of effector-deficient human MDE-8 mAbs] with FIG. 3A and FIG. 3B). Thus, effector-deficient human MDE-8 mAbs did not deplete platelets (FIG. 3D). Further, mice injected with effector-deficient human MDE-8 mAbs (IgG1 E269R and IgG2 N297A) showed no observable signs of infusion reactions (data not shown).

Similar results were obtained when using a different IgG subclass of effector-deficient human MDE-8 mAbs: MDE-8 (antibodies comprising the amino acids of SEQ ID NO: 69 together with SEQ ID NO: 67). Flow cytometric analysis of whole blood from CD32A transgenic mice before (FIG. 3E) and after (FIG. 3F) intravenous injection of native MDE-8 mAb IgG2 showed severe platelet depletion (FIG. 3F). Importantly, when the native MDE-8 mAb IgG2 was made effector-deficient, it no longer cleared circulating platelets (compare FIG. 3G [before injection] and FIG. 3H [after injection of effector-deficient human MDE-8 mAb] with FIG. 3E and FIG. 3F).

These results show that two representative IgG subclass types of effector-deficient human MDE-8 mAbs did not deplete circulating platelets (FIGS. 3D and 3H).

The results shown in FIG. 3 demonstrate that the effector domain of native MDE-8 IgG mAbs causes infusion reactions in CD32A mice, and such infusion reactions are eliminated by altering the IgG-Fc domain. Thus, ablating an anti-CD32a antibody's capacity to efficiently bind IgG Fc-receptors is beneficial in eliminating infusion reactions. Rendering MDE-8 mAbs effector-deficient also abrogates the antibodies' capacity to clear platelets from circulating blood, indicating such clearance is also mediated by the IgG-Fc domain, which, in the case of MDE-8, is immobilized on the surface of CD32A transgenic mouse platelets.

Effector-Deficient MDE-8 mAbs Protect CD32A Transgenic Mice from Immune Complex-Induced Thrombocytopenia

It was next determined that effector-deficient MDE-8 mAbs protect CD32A transgenic mice against immune complex-induced thrombocytopenia (drop in circulating platelet count). Three hours prior to immune complex challenge, CD32A mice were treated with vehicle phosphate buffered saline (PBS) or one of two representative effector-deficient human MDE-8 mAbs (100 micro-grams): 1) effector-deficient MDE-8 IgG1 E269R (SEQ ID NO: 69 together with SEQ ID NO: 65); or 2) effector-deficient MDE-8 IgG2 N297A (SEQ ID NO: 69 together with SEQ ID NO: 67). Mice were challenged with immune complex (M90+CD40L, total of 200 micro-grams), and whole blood was collected 30 minutes after challenge. FIG. 4 shows the results. In mice pre-treated with vehicle control, IC injection resulted in the mice having signs of severe shock (data not shown) and severe platelet depletion. Animals pre-treated with effector-deficient MDE-8 IgG1 E269R did not exhibit signs of IC-dependent infusion reactions or shock (data not shown). Moreover, as shown in FIG. 4B, mice pre-treated with effector-deficient MDE-8 IgG1 E269R did not experience IC-induced thrombocytopenia (i.e., platelets were not cleared by ICs; FIG. 4B). Due to infusion reactions, it was not possible to similarly test effector competent MDE-8 mAbs in native IgG1 format.

Similar results were obtained with effector-deficient MDE-8 IgG2 N297A. FIG. 4C shows the platelet count from a CD32A mouse pre-treated with vehicle control and following IC injection. FIG. 4D shows the post-IC injection platelet count of a CD32A mouse pre-treated with effector-deficient MDE-8 IgG2 N297. The data in FIG. 4 are representative of all animals tested.

FIG. 5 shows a bar graph depicting the drop in circulating platelets following IC injection into CD32A mice pre-treated with either vehicle or effector-deficient MDE-8 antibodies (pre-treatment at three hours prior to IC challenge). CD32A mice pre-treated with vehicle (PBS) became severely thrombocytopenic (FIGS. 5A and 5B, bars #1), whereas mice pre-treated with effector-deficient MDE-8 IgG1 E269R (FIG. 5A) or effector-deficient MDE-8 IgG2 N297A (FIG. 5B) were largely protected from loss of circulating platelets. Animal #1 in FIG. 5A and FIG. 5B was pre-treated with vehicle (PBS). M90+CD40L immune complexes were injected intravenously into all animals. Thirty minutes later, blood was drawn and platelets were counted. FIG. 5A shows that effector-deficient MDE-8 IgG1 E269R protects mice from immune complex-mediated thrombocytopenia (See FIG. 5A, columns 2, 3, and 4). FIG. 5B shows that effector-deficient MDE-8 IgG2 N297A protects mice from immune complex-mediated thrombocytopenia (See FIG. 5B, columns 2 and 3). Thus, two representative IgG subclasses (IgG1, IgG2) of effector-deficient MDE-8 mAbs protected CD32A transgenic mice from immune complex-induced thrombocytopenia.

Effector-Deficient MDE-8 Antibodies Protect CD32A Transgenic Mice from Pulmonary Thrombosis Caused by Immune Complexes (ICs)

CD32A transgenic mice were pre-treated with vehicle (PBS) or with 100 micro-grams of representative effector-deficient MDE-8 mAbs (SEQ ID NO: 69 together with SEQ ID NO: 65 or SEQ ID NO: 67). Three hours later, mice were challenged with M90+CD40L ICs (200 micro-grams). After thirty minutes, mice were sacrificed and their lungs harvested for analysis. FIG. 6A shows an H&E stained lung section from a mouse pre-treated with vehicle three hours prior to IC challenge. Pervasive occlusive pulmonary thrombi (*) were observed in mice pre-treated with vehicle. Surprisingly, mice pre-treated with effector-deficient MDE-8 IgG1 E269R exhibited normal lung anatomy without evidence of thrombosis (FIG. 6B). Effector-deficient MDE-8 IgG1 E269R pre-treated mice also showed normal blood vessels having abundant red blood cells in normal (healthy) alveolar tissue (FIG. 6B), as compared to vehicle treated mice (FIG. 6A), whose blood vessels were abnormal, with fewer numbers of red blood cells observed in blood vessels, as well as evidence of inflamed alveolar tissue.

Pulmonary thrombi per field were counted by H&E microscopy of mouse lungs following IC challenge. Four mice were injected with M90+CD40L IC. Animal #1 (FIG. 6C, bar 1; vehicle control) showed pervasive pulmonary thrombosis (mean of 20 per field), whereas animals #2-4 (FIG. 6C, bars 2-4) that were pre-treated with effector-deficient MDE-8 IgG1 E269R prior to IC challenge exhibited normal lung anatomy without evidence of thrombosis. The findings depicted in FIG. 6C also demonstrate that effector-deficient MDE-8 IgG1 E269R did not cause pulmonary thrombosis.

Similar results were obtained with effector-deficient MDE-8 IgG2 N297A. FIG. 7A shows an H&E stained lung section from a mouse which had been pre-treated with vehicle three hours prior to IC challenge. In FIG. 7A, pervasive occlusive pulmonary thrombi (*) were observed. In contrast, mice pre-treated with effector-deficient MDE-8 IgG2 N297A exhibited normal lung anatomy without evidence of thrombosis (FIG. 7B). Effector-deficient MDE-8 IgG2 N297A pre-treated mice also showed normal blood vessels having abundant red blood cells amidst healthy alveolar tissue (FIG. 7B), in contrast to the abnormal (with fewer numbers of red blood cells observed in blood vessels, as well as evidence of inflamed) alveolar tissue of the vehicle (PBS) pre-treated mice (FIG. 7A). The data in FIGS. 6 and 7 is representative of all animals tested.

FIG. 7C shows H&E microscopy of mouse lungs after IC challenge in mice pre-treated with vehicle or effector-deficient MDE-8 antibodies. Pulmonary thrombi per field were counted. Four mice were injected with M90+CD40L IC. Animal #1 (FIG. 7C, bar 1; control) showed pervasive pulmonary thrombosis (mean of 18.6 per field), whereas animals #2 and #3 (FIG. 7C, bars 2 and 3), which were pre-treated with effector-deficient MDE-8 IgG2 N297A, exhibited normal lung anatomy without evidence of thrombosis. These findings also demonstrate that MDE-8 IgG2 N297A mAb by itself did not cause pulmonary thrombosis.

Taken together, the data presented in Example 1 demonstrate: (1) that native (effector competent) anti-CD32a IgG mAbs cause infusions reactions and induce thrombocytopenia; (2) that altering MDE-8 mAbs to an effector-deficient format renders the IgG of choice infusion-safe and hemostatically safe (in that it does not induce thrombocytopenia); (3) that native MDE-8 mAb mediated infusion reactions and thrombocytopenia are dependent on the function of the IgG-Fc (effector) domain; (4) that effector-deficient MDE-8 IgG1 and IgG2 mAbs protect CD32A transgenic mice from immune complex-mediated infusion reactions, shock, thrombocytopenia, and thrombosis; and (5) that the CD32A IgG receptor largely controls infusion reactions, thrombocytopenia, thrombosis, and shock as mediated by ICs in these immunologically intact (e.g., having the full array of murine IgG receptors) CD32A transgenic mice. The dominant effect of the human CD32A transgene product over all other mouse IgG-Fc receptors (murine FcgammaRT, FcgammaRIIb, and FcgammaRIII), in response to thrombotic ICs, is an unexpected finding.

Example 2 Effector-Deficient Chimeric Monoclonal Antibody AT-10

The inventors have further demonstrated that native chimeric (mouse-human) AT-10 IgG mAbs cause infusion reactions in mice transgenic for CD32a (e.g., in CD32A mice). Observable signs of IgG-mediated infusion reactions in CD32A mice include hypothermia, rapid or shallow breathing, hunched posture, and locomotor dysfunction. Observable signs of severe infusion reactions include immobilization, convulsion, and (infrequently) fatality.

We show herein that altering the effector domain (i.e., the Fc domain) of the native AT-10 mAbs to an effector-deficient IgG format eliminated infusion reactions when administered to CD32A mice.

Moreover, when effector-deficient AT-10 mAbs were administered prior to challenge with immune complexes, the effector-deficient AT-10 mAbs prevented immune complex-induced infusion reactions, as well as thrombocytopenia and thrombotic shock.

Thus, effector-deficient monoclonal AT-10 antibodies may be used in place of native AT-10 antibodies to treat any CD32a mediated disease or disorder. The reasons include that the effector-deficient AT-10 antibodies will not elicit infusion reactions as observed with native AT-10 mAbs. Moreover, effector-deficient AT-10 mAbs may be used to treat and/or prevent any disease or disorder caused by immune complexes when given prophylactically or therapeutically.

Materials and Methods

Effector-competent and effector-deficient variants of AT-10 mAbs (IgG1 and IgG1 E269R, respectively) were injected intravenously (tail vein) into CD32A mice (as in Example 1). After injection (100 micro-grams), mice were monitored for 30 minutes for assessment of infusion reactions. Blood was collected (retro-orbitally) before, and 30 minutes after AT-10 mAb injection. Platelets were counted by flow cytometry from this collected blood. After 3 hours, some animals were injected with immune complexes (ICs, as in Example 1, 200 micro-grams), and blood was collected 30 minutes after injection. Platelets were again counted from this collected blood. Lungs were harvested 30 minutes after injection of ICs, processed for H&E staining, and examined microscopically for the presence of thrombi.

Results Effector-Deficient AT-10 mAbs do not Cause Infusion Reactions that are Seen with Effector Competent AT-10 Antibodies

When injected intravenously into CD32A transgenic mice, native chimeric AT-10 mAbs cause infusion reactions characterized by thrombocytopenia (FIG. 8, bar 1). Notably, these mice did not have hypothermia data not shown). Thrombocytopenia was ablated when effector-deficient chimeric AT-10 human IgG1 E269R mAbs were administered in lieu of native chimeric AT-10 human IgG1 (FIG. 8, column 2) (antibodies comprising the amino acids of SEQ ID NO: 22 together with SEQ ID NO: 16).

Flow cytometric analysis of whole blood from CD32A mice before (FIG. 9A) and after (FIG. 9B) intravenous injection of native chimeric AT-10 human IgG1 showed severe platelet depletion (FIG. 9B) despite having no hypothermia. Importantly, when native chimeric AT-10 human IgG1 mAbs were made effector-deficient, they no longer reduced circulating platelets (compare FIG. 9C [before injection] and FIG. 9D [after injection of effector-deficient chimeric AT-10 human IgG1 mAbs]). Thus, effector-deficient AT-10 mAbs did not deplete platelets. This data demonstrates that the IgG effector domain is responsible for AT-10 IgG-induced thrombocytopenia.

These experiments demonstrate that thrombocytopenia (a drop in platelet count) is independent of and, in this case, a more sensitive indicator of infusion reaction than temperature drop, since native AT-10 mAbs in IgG1 format failed to cause hypothermia (data not shown) but caused severe platelet depletion. Importantly, effector-deficient AT-10 mAbs did not deplete platelets (i.e., cause thrombocytopenia) like their effector competent counterparts.

The results shown in FIGS. 8 and 9 demonstrate that the effector region of native AT-10 IgG mAbs mediates infusion reactions in CD32A mice, and that such infusion reactions are eliminated by altering the IgG-Fc region. Thus, ablating an anti-CD32a antibody's capacity to efficiently bind IgG Fc-receptors is beneficial in eliminating infusion reactions.

Effector-Deficient AT-10 mAbs Protect CD32A Transgenic Mice from Immune Complex-Induced Thrombocytopenia

Next it was demonstrated that effector-deficient AT-10 mAbs were capable of protecting CD32A transgenic mice from immune complex-induced thrombocytopenia (FIG. 10). Three hours prior to immune complex challenge, mice were treated with PBS vehicle or an effector-deficient AT-10 mAb (IgG1 E269R,) (antibodies comprising the amino acid of SEQ ID NO: 22 together with SEQ ID NO: 16). Immune complexes (M90+CD40L (as in Example 1); 200 micro-grams) were injected intravenously and whole blood was collected 30 minutes after IC challenge. Platelets were counted from this collected blood.

FIG. 10 shows a bar graph depicting the % drop in circulating platelets following IC injection into CD32A mice pre-treated with either vehicle or effector-deficient chimeric AT-10 human IgG1 E269R antibodies. CD32A mice pre-treated with vehicle (PBS) became severely thrombocytopenic (FIG. 10 column 1), whereas mice pre-treated with effector-deficient chimeric AT-10 human IgG1 E269R (FIG. 10 columns 2 and 3) were largely protected from loss of circulating platelets. Effector-deficient chimeric AT-10 human IgG1 E269R protected mice from immune complex-induced thrombocytopenia (FIG. 10, columns 2 and 3 compared to control, column 1.

FIG. 11 shows a flow cytometric analysis of circulating platelets following IC injection into CD32A mice pre-treated with either vehicle or effector-deficient AT-10 antibodies as described above. FIG. 11A shows platelets depletion from a mouse that received vehicle. FIG. 11B shows that animals pre-treated with effector-deficient chimeric AT-10 human IgG1 E269R did not experience thrombocytopenia in response to IC injection. Furthermore, effector-deficient chimeric AT-10 human IgG1 E269R pre-treatment completely protected CD32A mice from observable signs of IC-mediated infusion reaction. Chimeric AT-10 human IgG1 E269R-treated animals appeared unaffected by IC injection, whereas vehicle treated controls showed signs of imparied mobility, hunched posture, and shallow and rapid breathing, consistent with shock.

Effector-Deficient AT-10 Antibodies Protect CD32A Transgenic Mice from Pulmonary Thrombosis Caused by Immune Complexes (ICs)

Mice were pre-treated with vehicle (PBS) or with effector-deficient AT-10 mAbs (antibodies comprising the amino acids of SEQ ID NO: 22 together with SEQ ID NO: 16). Three hours later, mice were challenged with M90+CD40L IC (as in Example 1; 200 micro-grams). After thirty minutes, mice were sacrificed and their lungs removed for analysis. FIG. 12A shows a representative H&E stained lung section from a mouse pre-treated with vehicle 3 hours prior to IC challenge. Pervasive occlusive pulmonary thrombi (*) were detected in vehicle-treated mice. Surprisingly, mice pre-treated with effector-deficient AT-10 IgG1 E269R exhibited normal lung anatomy without evidence of thrombosis (FIG. 12B), despite the fact that these mice are immunologically intact (i.e., have the full repertoire of normal mouse IgG receptors, in addition to human CD32A). Effector-deficient AT-10 IgG1 E269R pre-treated mice also showed normal blood vessels having abundant red blood cells amidst healthy alveolar tissue (FIG. 12B), as compared to control (vehicle-treated) mice (FIG. 12A). These results demonstrate that effector-deficient chimeric AT-10 human IgG1 E269R mAbs are capable of protecting against IC-induced thrombosis.

FIG. 12C shows H&E microscopy of mouse lungs following IC injection into CD32A mice pre-treated with either vehicle (control) or effector-deficient chimeric AT-10 antibodies as described above (See FIGS. 12A and 12B). Animal #1 (FIG. 12C, bar 1; control) showed pervasive pulmonary thrombosis (mean of 17.6 clots per field), whereas animals #2 and #3 (FIG. 12C, bars 2 and 3), which were pre-treated with effector-deficient chimeric AT-10 human IgG1 E269R, exhibited normal lung anatomy without evidence of thrombosis.

Humanized Effector-Deficient AT-10 mAbs

An effector-deficient humanized AT-10 IgG1 E269R mAb (“hAT-10”) was made and tested (antibodies comprising the amino acids of SEQ ID NO: 24 together with SEQ ID NO: 20). In FIG. 13A, hAT-10 E269R mAb (116 μg) was administered to CD32A mice and core body temperature of the mice was assessed over time. hAT-10 E269R mAbs did not cause hypothermia (an indicator of infusion reaction). In addition to not exhibiting hypothermia, these animals exhibited no other signs of having infusion reactions. FIG. 13B shows the results of a study where platelets from CD32A mice were assessed before and after hAT-10 E269R injection (116 micro-grams). hAT-10 had no effect on circulating platelet counts (compare FIG. 13B with FIG. 13C).

Furthermore, hAT-10 E269R completely protects mice against M90+CD40L IC-induced thrombocytopenia. Control animals that received vehicle (PBS control) pre-treatment became unconscious within 10 minutes of receiving IC challenge and subsequently showed signs consistent with severe shock. In contrast, mice pre-treated with hAT-10 E269R appeared unaffected by IC challenge (data not shown). hAT-10 E269R pre-treatment also protected CD32A mice from thrombocytopenia (compare FIG. 13D showing platelet loss in vehicle-treated group and FIG. 13E showing no platelet loss in hAT-10 E269R-treated animals).

Finally, humanized effector-deficient AT-10 IgG1 E269R (hAT-10 E269R) antibody protected mice from immune complex-induced pulmonary thrombosis. As observed with AT-10 chimeric antibody (FIG. 12), pre-treatment with hAT-10 E269R completely prevented pulmonary thrombosis in CD32A mice after IC challenge (M90+CD40L; as in Example 1; 200 micro-grams). FIG. 13F shows significant thrombi in lungs of control treated mice and nearly complete lack of thrombi in hAT-10 E269R treated mice. See, also, FIG. 13G showing pervasive pulmonary thrombosis (mean of 24.4 clots per field) in control treated mice as compared to a lack of thrombi in mice pre-treated with hAT-10 E269R (FIG. 13H).

Taken together, the data presented in Example 2 demonstrate: (1) that native (effector competent) anti-CD32a IgG mAb AT-10 causes infusions reactions characterized by thrombocytopenia; (2) that altering AT-10 mAb to be effector-deficient renders AT-10 infusion-safe and hemostatically safe (in that it does not induce thrombocytopenia); (3) that native (effector competent) AT-10 antibody mediated infusion reactions and thrombocytopenia are dependent on the function of the IgG-Fc (effector) domain; (4) that effector-deficient AT-10 IgG mAb protects CD32A transgenic mice from immune complex-mediated infusion reactions, thrombocytopenia, and thrombosis; and (5) that the CD32a IgG receptor largely controls infusion reactions, thrombocytopenia, thrombosis, and shock, as mediated by ICs in these immunologically intact CD32A mice.

Example 3 Effector-Deficient Chimeric Monoclonal Antibody IV.3

The inventors have further demonstrated that native chimeric IV.3 mAbs cause infusion reactions in mice transgenic for its antigen (i.e., CD32A mice). Observable signs of IgG-mediated infusion reactions in CD32A mice include hypothermia, rapid or shallow breathing, hunched posture, and locomotor dysfunction; observable signs of severe infusion reactions also include impaired mobility, convulsion, apparent loss of consciousness, and (infrequently) fatality.

We show herein that altering the effector domain (i.e., Fc domain) of chimeric IV.3 to an effector-deficient IgG format eliminated infusion reactions following administration to CD32A mice.

Moreover, when effector-deficient IV.3 was provided to subjects prior to challenge with immune complexes, the effector-deficient IV.3 mAbs prevented immune complex-induced infusion reactions, as well as thrombocytopenia and thrombotic shock.

Thus, effector-deficient monoclonal IV.3 antibodies should be used in place of native IV.3 antibodies to treat any CD32a mediated disease or disorder. The reasons include that the effector-deficient IV.3 antibodies will not elicit infusion reactions as observed with native IV.3 mAbs. Moreover, effector-deficient IV.3 may be used to treat and/or prevent any disease or disorder caused by immune complexes when given prophylactically or therapeutically.

Materials and Methods

In this set of experiments, effector-competent and effector-deficient variants of chimeric IV.3 mAbs (human IgG2 and human IgG2 N297A, respectively) were injected intravenously (tail vein) into human CD32A transgenic mice (as in Example 1). After injection (100 micro-grams), animals were monitored for 30 minutes for assessment of infusion reactions. Blood was collected (retro-orbitally) before and 30 minutes after IV.3 mAb injection. Platelets were then counted by flow cytometry from this collected blood. After 3 hours, some animals were injected with immune complexes (ICs, as in Example 1, 200 micro-grams), after which (30 minutes) platelets were again counted. Lungs were then harvested, processed for H&E staining, and examined microscopically for the presence of thrombi.

Results Effector-Deficient IV.3 mAbs do not Cause Infusion Reactions that are Seen with Effector Competent IV.3 Antibodies

We discovered that, when injected intravenously into CD32A transgenic mice, effector competent chimeric IV.3 human IgG2 mAb causes infusion reactions in a dose-dependent manner, as characterized by thrombocytopenia without hypothermia. FIG. 14 shows that, following intravenous injection of chimeric IV.3 in native human IgG2 format, CD32A transgenic mice became severely thrombocytopenic (FIG. 14A, solid bars). This thrombocytopenia was largely ablated when effector-deficient chimeric IV.3 human IgG2 N297A mAb (antibodies comprising the amino acids of SEQ ID NO: 51 together with SEQ ID NO: 45) was administered in lieu of native chimeric IV.3 (FIG. 14A, open bars). FIG. 14B shows that neither native chimeric IV.3 human IgG2 nor its effector-deficient (IV.3 IgG2 N297A) format caused hypothermia in CD32A transgenic mice.

These results again suggest that a drop in platelet count is independent of and, in this case, more sensitive than core body temperature drop as indicator for infusion reaction to antibodies that interact with platelets in vivo.

Flow cytometric analysis of whole blood from CD32A transgenic mice before (FIG. 15A) and after (FIG. 15B) intravenous injection of native chimeric IV.3 in human IgG2 showed severe platelet depletion (FIG. 15B). Importantly, when native chimeric IV.3 IgG2 mAb was made effector-deficient, it no longer reduced circulating platelets (compare FIG. 15C [before injection] and FIG. 15D [after injection of effector-deficient chimeric IV.3 mAbs]). Thus, effector-deficient IV.3 mAbs did not deplete platelets (FIG. 15D). This data demonstrates that the IgG effector domain is responsible for the IV.3 IgG-induced thrombocytopenia.

The results shown in FIGS. 14 and 15 demonstrate that the effector domain of native IV.3 IgG mAbs cause infusion reactions in CD32A mice, and such infusion reactions are eliminated by altering the IgG-Fc domain. Thus, ablating an anti-CD32a antibody's capacity to efficiently bind IgG Fc-receptors is beneficial in eliminating infusion reactions. Rendering IV.3 mAbs effector-deficient also abrogates the antibodies' capacity to clear platelets from circulating blood, indicating such clearance is also mediated by the IgG-Fc domain, which, in the case of IV.3, is immobilized on the surface of CD32A transgenic mouse platelets.

Effector-Deficient IV.3 mAbs Protect CD32A Transgenic Mice from Immune Complex-Induced Thrombocytopenia

It was next determined that effector-deficient chimeric IV.3 mAbs protect CD32A transgenic mice from immune complex-induced thrombocytopenia. Three hours prior to immune complex challenge, CD32A transgenic mice were pre-treated with PBS vehicle or 100 micro-grams of a representative effector-deficient chimeric IV.3 IgG2 N297A (antibodies comprising the amino acids of SEQ ID NO: 51 together with SEQ ID NO: 45). Whole blood was collected 30 minutes after mice were challenged with immune complexes (M90+CD40L, as in Example 1, 200 micro-grams). FIG. 16A shows platelet depletion in a whole blood sample from a mouse that received vehicle. FIG. 16B shows that animals pre-treated with chimeric IV.3 IgG2 N297A did not experience thrombocytopenia in response to ICs.

FIG. 17 shows a bar graph depicting the % drop in circulating platelets following IC injection (M90+CD40L, as in Example 1, 200 micro-grams) into CD32A mice pre-treated with either vehicle or effector-deficient chimeric IV.3 antibodies as described above. CD32A mice pre-treated with vehicle (PBS) became severely thrombocytopenic (FIG. 17, bar 1), whereas mice pre-treated with effector-deficient chimeric IV.3 IgG2 N297A (FIG. 17, bars 2, 3 and 4) were largely protected from loss of circulating platelets. Thus, effector-deficient chimeric IV.3 human IgG2 N297A protected mice from immune complex-induced thrombocytopenia (FIG. 17).

Effector-Deficient Chimeric IV.3 Antibodies Protect CD32A Transgenic Mice from Pulmonary Thrombosis Caused by Immune Complexes (ICs)

In this experiment, CD32A mice were pre-treated with vehicle or with 100 micro-grams of effector-deficient chimeric IV.3 human IgG2 N297A mAb (SEQ ID NO: 51 together with SEQ ID NO: 45). Three hours later, pre-treated mice were challenged with M90+CD40L IC (as in Example 1, 200 micro-grams). Thirty minutes later, mice were sacrificed and their lungs removed for analysis. FIG. 18A shows an H&E stained lung section from a mouse pre-treated with vehicle 3 hours prior to IC challenge. Pervasive occlusive pulmonary thrombi (*) were detected in vehicle-treated mice. Surprisingly, mice pre-treated with effector-deficient chimeric IV.3 human IgG2 N297A exhibited normal lung anatomy without evidence of thrombosis (FIG. 18B). Chimeric IV.3 IgG2 human N297A-pre-treated mice also showed normal blood vessels having abundant red blood cells amidst healthy alveolar tissue (FIG. 18B), as compared to vehicle treated mice (FIG. 18A), which exhibited abnormal and occluded blood vessels. Notably, these mice were immunologically intact (having the full array of naturally occurring mouse IgG-Fc receptors), demonstrating the dominance of CD32a in IC-induced thrombocytopenia, thrombosis, and shock.

In FIG. 18C, the average number of pulmonary thrombi per 10 fields was determined by H&E microscopy of mouse lungs following IC challenge. Four mice were injected with M90+CD40L IC as described above. Animal #1 (PBS pre-treated control) showed pervasive pulmonary thrombosis (mean of 17.6 clots per field), whereas animals #2, #3, and #4 which were pre-treated with effector-deficient chimeric IV.3 human IgG2 N297A, exhibited normal lung anatomy without evidence of thrombosis.

Taken together, the data presented in Example 3 demonstrate: (1) that native chimeric IV.3 anti-CD32a IgG2 mAb causes infusions reactions and induces thrombocytopenia; (2) that altering chimeric IV.3 mAb to an effector-deficient format renders chimeric IV.3 infusion-safe and hemostatically safe (in that it does not induce thrombocytopenia); (3) that IV.3 mediated infusion reactions and thrombocytopenia are dependent on the function of the IgG-Fc (effector) domain; (4) that effector-deficient chimeric IV.3 IgG mAbs protects CD32A transgenic mice from immune complex-mediated infusion reactions, thrombocytopenia, thrombosis, and shock.

Example 4

Anti-CD32a mAbs potently inhibit CD32a-mediated immune complex-induced human platelet aggregation and degranulation.

In this example we analyzed immune complex-induced human platelet aggregation and degranulation in vitro to assess the potency and efficacy of anti-CD32a mAbs.

Methods

Platelet-activating immune complexes (ICs) were prepared by combining CD40 ligand (CD40L, also called CD154), human platelet factor 4 (hPF4), human beta 2-Glycoprotein I (beta 2-GPI), or TNFalpha antibodies with their respective ligands typically at balanced stoichiometry (100-1000 nM). The following types of immune complexes were tested: (1) M90 anti-CD40L mAb+CD40L; (2) M91 anti-CD40L mAb+CD40L; (3) M90 anti-CD40L mAb+M91 anti-CD40L mAb+CD40L (a polyclonal immune complex); (4) anti-hPF4 mAb+hPF4+0.1 U/ml heparin (an HIT-like IC); (5) polyclonal anti-beta 2-GPI+beta 2-GPI (an APS-like IC); (6) infliximab+TNFalpha (a therapeutic mAb-like IC); (7) adalimumab+TNFalpha (a therapeutic mAb-like IC); and (8) goat F(ab′)2-anti-human-IgG-F(ab′)2+infliximab (to mimic anti-therapeutic antibody IC activity).

Isolated platelets were assessed via light-transmission aggregometry as follows. Platelets were acquired from healthy human donors (n=10) following informed consent, washed and suspended in assay buffer. Platelets were placed in cuvettes in the aggregometer and allowed to incubate at 37° C. until a stable baseline was achieved.

Anti-CD32a antibodies or saline were added to the cuvette 5-10 minutes before the addition of platelet-activating immune complexes. Following the addition of immune complexes, aggregation traces were monitored for at least 5 minutes. In some cases where CD32a mAbs prevented immune complex-induced aggregation, the capacity of the platelets to aggregate was confirmed by the addition of the standard agonist collagen (7 micro-grams/milliliter final concentration).

Results

In FIG. 19, 500 nM M90+CD40L IC activated CD32a on washed human platelets, leading to aggregation, which was not blocked by a control mAb (recombinant rabbit IgG) FIG. 19 (line 1). Platelet aggregation was completely blocked by mouse IV.3 mIgG2b (FIG. 19, line 2) and by native chimeric IV.3 hIgG1 (FIG. 19, line 3), which display similar potency (<5 nM required). This data demonstrates that cloned native chimeric IV.3 hIgG1 has CD32a blocking activity comparable to that of the parent mouse monoclonal antibody.

In FIG. 20, 250 nM M90+CD40L IC potently induced CD32a-dependent aggregation (FIG. 20, line 1), which was blocked by 7 nM aglycosylated mouse IV.3 mIgG2b (FIG. 20, line 2). These results suggest that deglycosylation of the “Fc” effector domain of mouse IV.3 mIgG2b mAb, which renders the antibody effector-deficient, does not significantly alter its potency in blocking platelet CD32a (i.e., its Fab-dependent activity).

In FIG. 21, 500 nM M90+CD40L IC induced aggregation (FIG. 21, line 1), which was blocked by native chimeric IV.3 hIgG2 (FIG. 21, lines 2, 3, 4). Aggregation of platelets from a second donor tested with 500 nM M91+CD40L IC was also completely inhibited by native chimeric IV.3 hIgG2 (data not shown).

In FIG. 22, 500 nM M90+CD40L IC-induced aggregation (FIG. 22, line 1) is blocked by 3.3 nM (FIG. 22, line 2) and by 1.7 nM (FIG. 22, line 3) effector-deficient chimeric IV.3 hIgG2 N297A mAb (SEQ ID NO: 51 together with SEQ ID NO: 45). Collagen (designated by * here and below), added at 19 min, demonstrated the anti-CD32a mAb-treated platelets remained aggregation competent.

In FIG. 23, 500 nM M90+CD40L IC induced aggregation (FIG. 23, line 1) is blocked by 13 nM effector-deficient chimeric AT-10 hIgG1 E269R (FIG. 23, line 2) mAb (SEQ ID NO: 22 together with SEQ ID NO; 16). Also, native chimeric AT-10 hIgG1, hIgG2, and effector-deficient chimeric hIgG2 N297A formats (SEQ ID NO: 22 together with SEQ ID NO: 18) gave similar results with platelets from other donors (data not shown).

In FIG. 24, an IC composed of a 700 nM mix of M90+M91 plus CD40L caused platelet aggregation (FIG. 24, line 1). The activity of this IC was completely blocked by less than 3 nM of effector-deficient human MDE-8 IgG1 E269R (SEQ ID NO: 69 together with SEQ ID NO: 65) (FIG. 24, line 2). Collagen, added at 15 min, demonstrated aggregation competence (FIG. 24, line 2*). Native human MDE-8 IgG1, IgG2, and effector-deficient IgG2 N297A (SEQ ID NO: 69 together with SEQ ID NO: 67) similarly blocked IC-induced aggregation (data not shown).

In FIG. 25, 500 nM M90+CD40L IC-induced aggregation (FIG. 25, line 1) was inhibited similarly by 3 nM effector-deficient humanized IV.3.1 IgG1 E269R (SEQ ID NO: 53 together with SEQ ID NO: 47, FIG. 25, line 2) and by 3 nM mouse IV.3 mIgG2b (FIG. 25, line 3) mAbs. An identical concentration (3 nM) of effector-deficient humanized IV.3.2 IgG1 E269R mAbs (SEQ ID NO: 53 together with SEQ ID NO: 49) also inhibited the activity of this IC (data not shown). This data demonstrates similar potency between humanized and mouse IV.3 mAbs.

In FIG. 26, 500 nM M90+CD40L IC-induced aggregation (FIG. 26, line 1) was not inhibited by 2 nM effector-deficient humanized IV.3.1 IgG1 E269R mAb (SEQ ID NO: 53 together with SEQ ID NO: 47, FIG. 26, line 2) but was inhibited by 2 nM mouse IV.3 mIgG2b mAb (FIG. 26, line 3). Collagen, added at 10.5 min, demonstrated platelet aggregation competence.

In FIG. 27, M90+CD40L (500 nM) IC-induced aggregation (FIG. 27, line 1) was blocked by 6 nM effector-deficient humanized IV.3.1 IgG1 E269R mAb (SEQ ID NO: 53 together with SEQ ID NO: 47, FIG. 27, line 2) Collagen (*) was added (FIG. 27, line 2) at 11 min and demonstrated platelet aggregation competence.

In FIG. 28, an IC composed of a 1000 nM mix of M90+M91 plus CD40L caused platelet aggregation (FIG. 28, line 1). The activity of this IC was blocked by 25 nM effector-deficient humanized IV.3.1 IgG1 E269R mAb (SEQ ID NO: 53 together with SEQ ID NO: 47, FIG. 28, line 2) and by 25 nM mouse IV.3 mIgG2b (FIG. 28, line 3). Negative control (no IC added; FIG. 28, line 4) did not aggregate.

In FIG. 29, 250 nM hPF4+anti-hPF4+heparin (0.1 Units/milliliter), an HIT-like IC (FIG. 29, line 1), was completely blocked by 40 nM of effector-deficient humanized IV.3.1 IgG1 E269R (SEQ ID NO: 53 together with SEQ ID NO: 47, FIG. 29, line 2). Collagen was added (FIG. 29, line 2) at 10.5 min. Effector-deficient humanized IV.3.2 IgG1 E269R mAbs (SEQ ID NO: 53 together with SEQ ID NO: 49) also inhibited the activity of this IC (data not shown).

In FIG. 30, 500 nM anti-human beta 2-GPI polyclonal antibody+125 nM human beta 2-GPI IC (an APS-like IC) induced robust platelet aggregation (FIG. 30, line 1) which was blocked both by 33 nM of effector-deficient humanized IV.3.1 IgG1 E269R mAb (SEQ ID NO: 53 together with SEQ ID NO: 47, FIG. 30, line 2) and by 50 nM of effector-deficient human MDE-8 IgG1 E269R (SEQ ID NO: 69 together with SEQ ID NO: 65, FIG. 30, line 3).

In FIG. 31, M90+CD40L (500 nM) IC-induced aggregation (FIG. 31, line 1) was inhibited by 15 nM effector-deficient humanized AT-10 IgG1 E269R mAb (SEQ ID NO: 24 together with SEQ ID NO: 20, FIG. 31, line 2). Addition of 375 nM of the F(ab′)2 fragment of goat anti-human-F(ab′)2 (designated as #; added at 16 min), which lacks an Fc-domain, cause platelet aggregation thus demonstrating platelet surface localization of effector-deficient humanized AT-10 IgG1 E269R as well as aggregation competence.

Taken together, the results depicted by FIG. 19-31 demonstrate that several different types of immune complexes (ICs) are capable of inducing platelet aggregation in a CD32a-dependent manner. These ICs are potently blocked by chimeric or humanized IV.3, by chimeric or humanized AT-10, and by MDE-8, including IgG1 and IgG2 isotype subclasses, in both effector-competent and effector-deficient formats. Because humanized AT-10 and humanized IV.3 mAbs exhibited CD32a blocking activity comparable to that of their parent murine mAbs, these previously undescribed and novel mAbs may be useful for treatment of human disorders in which immune complexes play a pathologic role via CD32a.

When considered together, the in vivo (mouse) and in vitro (aggregation, degranulation) data also demonstrate that effector-deficient formats of IV.3, AT-10, and MDE-8, whether in IgG1 or IgG2 format, and whether chimeric, humanized, or fully human, can be expected to have safe in vivo administration profiles while providing potent blockade of CD32a, thus preventing CD32a activation induced by ICs or by immobilized IgG.

Combined AT-10, IV.3 and MDE-8 mAbs do not Activate CD32a.

We next considered whether the effector-deficient chimeric, humanized, and human anti-CD32a mAbs described herein were capable, when combined, of activating CD32a (i.e., by directly multimerizing or clustering the receptor). To this end, we combined 2 nM humanized AT-10 (SEQ ID NO: 24 together with SEQ ID NO: 20), 150 nM humanized IV.3.1 (SEQ ID NO: 53 together with SEQ ID NO: 47), and 150 nM human MDE-8 (SEQ ID NO: 69 together with SEQ ID NO: 65), all in effector-deficient IgG1 E269R format, and exposed the combination of these anti-CD32a mAbs to washed human platelets. FIG. 32 shows that 500 nM M90+CD40L IC induced robust platelet aggregation (FIG. 32, line 1), while combined anti-CD32a mAbs did not cause aggregation (FIG. 32, line 2). Collagen (*), added at 18 min, demonstrated aggregation competence. FIG. 33 shows that the combination of 300 nM effector-deficient chimeric AT-10 hIgG1 E269R (SEQ ID NO: 22 together with SEQ ID NO: 16), 300 nM effector-deficient chimeric IV.3 hIgG2 N297A (SEQ ID NO: 51 together with SEQ ID NO: 45), and 300 nM effector-deficient human MDE-8 IgG1 E269R (SEQ ID NO: 69 together with SEQ ID NO: 65) also failed to induce platelet aggregation, whereas collagen (*) succeeded.

We next examined the capacity of combined CD32a mAbs to induce platelet degranulation, as occurs when CD32a is clustered by ICs. We also evaluated the capacity of these anti-CD32a mAbs to prevent platelet degranulation caused by therapeutic TNFalpha antibodies complexed with TNFalpha (100 nM). To that end, we tested murine IV.3 mIgG2b, effector-deficient humanized IV.3.1 hIgG1 E269R (SEQ ID NO: 53 together with SEQ ID NO: 47), effector-deficient chimeric AT-10 hIgG1 E269R (SEQ ID NO: 22 together with SEQ ID NO: 16, and effector-deficient human MDE-8 IgG1 E269R (SEQ ID NO: 69 together with SEQ ID NO: 65), as well as the combination of these four mAbs (all at 100 nM), for their capacity to activate washed human platelets, as measured by degranulation in the serotonin release assay (FIG. 34). The results showed that all tested anti-CD32a mAbs prevented TNFalpha-immune-complex induced platelet degranulation, and that the combination of all mAbs failed to degranulate platelets. FIG. 34.

Further, a combination of 25 nM humanized IV.3.1 (SEQ ID NO: 53 together with SEQ ID NO: 47), 90 nM humanized AT-10 (SEQ ID NO: 24 together with SEQ ID NO: 20), and 75 nM human MDE-8 (SEQ ID NO: 69 together with SEQ ID NO: 65), all in effector-deficient IgG1 E269R format, was also similarly tested with the same result (i.e., no activation of CD32a; data not shown).

Each of the tested mAbs blocked infliximab and adalimumab anti-TNFalpha IC-induced platelet activation. The combination of four anti-CD32a mAbs (mouse IV.3, humanized IV.3, chimeric AT-10, and human MDE-8) failed to cause any platelet activation (FIG. 34).

Taken together, the results shown in FIGS. 32-34 indicate that the tested mAbs are compatible in that they do not synergistically cluster CD32a to the point of activation, suggesting that these mAbs could potentially be delivered to patients without synergistic activation. Furthermore, the compatability of these mAbs provides a progressive treatment course for anti-CD32a therapy, wherein patients developing immune reactivity to a first therapeutic anti-CD32a mAb are provided with follow-up therapeutics compatible for long term treatment of chronic immune complex-mediated disorders.

Although humanized and human antibodies used for therapy in patients with immune complex-mediated disorders are expected to be less immunogenic, the evidence suggests that many such patients nevertheless develop immune reactions to the therapeutic antibody (e.g., anti-therapeutic-antibody-antibodies, or ATA). These host response antibodies can form immune complexes that activate CD32a; however, the effector-deficient CD32a mAbs described herein are candidates for use in protecting patients from these ATA immune complexes.

Following this rationale, we examined the capacity of anti-CD32a mAbs to prevent platelet degranulation induced by ICs formed from infliximab and F(ab′)2 fragments of goat anti-human IgG-F(ab′)2 antibodies, wherein the only functional Fc-domain of such ICs is that of the therapeutic mAb, infliximab. FIG. 35 shows that infliximab+goat anti-human IgG F(ab′)2 ICs induced platelet degranulation (FIG. 35, first column). The activity of this IC was blocked by mouse IV.3 mIgG2b mAb (FIG. 35, second column), by effector-deficient human MDE-8 IgG1 E269R (SEQ ID NO: 69 together with SEQ ID NO: 65, FIG. 35, third column), by effector-deficient chimeric AT-10 hIgG1 E269R (SEQ ID NO: 22 together with SEQ ID NO: 16, FIG. 35, fourth column), and by effector-deficient humanized IV.3.1 hIgG1 E269R (SEQ ID NO: 53 together with SEQ ID NO: 47, FIG. 35, fifth column). These results demonstrate that CD32a blockade can prevent activation of platelets by ICs formed from antibodies that cluster the therapeutic mAb, infliximab, and that the effector-deficient CD32a antibodies of the present invention are useful in methods to prevent activation of platelets by ICs, and in particular, by ICs formed from clusters of therapeutic non-CD32a monoclonal antibodies.

Furthermore, patients who are immunologically reactive to such therapeutic non-CD32a mAbs are typically transitioned, or “switched” to alternative therapeutic mAbs having the same antigen target, as is the case in anti-TNF alpha therapy, where a reactive patient might be switched, for example, from infliximab to adalimumab. This concern may require lengthy treatment gaps to ensure that residual previous therapeutic antibody is no longer present. However, our data suggests that an immune reactive recipient (i.e., a patient having an immune reaction to administered therapeutic antibodies) could safely be switched to one of the effector-deficient CD32a antibodies described herein with no treatment gap, and also that a patient could be treated with multiple effector-deficient CD32a antibodies as described herein without concern for synergistic platelet activation.

Following this rationale, we injected the combination of three anti-CD32a mAbs into CD32A transgenic mice and examined core body temperature and platelet counts as measures of possible synergistic infusion reactions. Effector-deficient chimeric AT-10 hIgG1 E269R (SEQ ID NO: 22 together with SEQ ID NO: 16), effector-deficient chimeric IV.3 hIgG2 N297A (SEQ ID NO: 51 together with SEQ ID NO: 45), and effector-deficient human MDE-8 IgG1 E269R (SEQ ID NO: 69 together with SEQ ID NO: 65) were premixed and injected intravenously as a single bolus into two CD32A transgenic mice. The first animal received 50 micro-grams of each mAb (total of 150 micro-grams of anti-CD32a IgG injected). The second animal received 100 micro-grams of each mAb (300 micro-grams total IgG injected). Platelet counts (in whole blood) of each animal were measured before (FIGS. 36A and 36C) and 30 minutes after mAb injection (FIG. 36B=50 micro-grams×3, and FIG. 36D=100 micro-grams×3). Gate P1 identifies platelets (gate P4 is other blood cells). FIG. 36E shows core body temperature in CD32A transgenic mice as monitored for 30 minutes following injection of effector-deficient mAbs. These results show that these effector-deficient anti-CD32a clones (i.e., IV.3, AT-10, MDE-8), when combined, do not confer the capacity either to cluster CD32a or to induce thrombocytopenia in CD32A mice.

Taken together, the results depicted by FIGS. 32-36 demonstrate a surprising functional compatability of IV.3, AT-10, and MDE-8, such that, when combined, these antibodies retain their non-activating profile, both in vitro and in vivo, thus providing a therapeutic strategy for continued anti-CD32a immunotherapy, for example, in the presence of anti-drug antibodies (ATA).

EQUIVALENTS

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the embodiments. The foregoing description and Examples detail certain embodiments and describes the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the embodiment may be practiced in many ways and should be construed in accordance with the appended claims and any equivalents thereof.

As used herein, the term “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated. The term “about” generally refers to a range of numerical values (e.g., +/−5-10% of the recited range) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure. 

1. A method for blocking CD32a and/or preventing CD32a activation in a human subject comprising: administering a therapeutically effective amount of an effector-deficient anti-CD32a monoclonal antibody to a human subject, wherein the antibody comprises at least a portion of an Fc region and is effector-deficient, thereby blocking CD32a and/or preventing CD32a activation.
 2. The method of claim 1, wherein the effector-deficient antibody satisfies both the IgG Immune Complex Test and the Immobilized IgG Test, and wherein the FC region of the effector-deficient antibody has been altered so as to reduce or eliminate Fc-binding to CD16, CD32, and/or CD64 type IgG receptors.
 3. The method of claim 1, wherein the subject has a CD32a-mediated disease or disorder that is an IgG-mediated hemostatic disorder.
 4. The method of claim 3, wherein the hemostatic disorder is thrombosis with or without thrombocytopenia.
 5. The method of claim 3, wherein the hemostatic disorder is selected from the group consisting of IgG-mediated-thrombocytopenia, immune-mediated-thrombocytopenia (ITP), antiphospholipid syndrome (APS), anti-platelet-antibody disorders, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia with thrombosis (HITT), cancer-induced platelet activation, cancer-induced hypercoagulability, platelet-mediated tumor cell metastasis, and platelet-mediated cancer metastasis.
 6. The method of claim 1, wherein the subject has a CD32a-mediated disease or disorder characterized by IgG-Fc-mediated activation of CD32a on platelets, monocytes, neutrophils, basophils, eosinophils, macrophages, dendritic cells, synovial cells, mast cells, or dermal microvascular endothelial cells.
 7. The method of claim 1, wherein the subject has a CD32a-mediated disease or disorder that is an IgG-mediated immune, autoimmune, or inflammatory disease or disorder.
 8. The method of claim 7, wherein the IgG-mediated immune, autoimmune or inflammatory disorder is selected from the group consisting of rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, antiphospholipid syndrome (APS), osteoarthritis, systemic lupus erythematous (SLE), lupus nephritis, IgG antibody-induced anemia, and IgG-mediated cytopenia.
 9. The method of claim 1, wherein the subject has a CD32a-mediated disease or disorder that is an IgG immune complex-mediated disease or disorder.
 10. The method of claim 9, wherein the IgG immune complex-mediated disease or disorder is an anti-therapeutic-antibody (ATA) response caused by administration of a non-anti-CD32a monoclonal antibody or fragment thereof.
 11. The method of claim 10, wherein the non-anti-CD32a antibody is infliximab, adalimumab, certolizumab pegol (antibody-like), golimumab, etanercept (antibody-like), ustekinumab, omalizumab, or bevacizumab.
 12. The method of claim 10, wherein the effector deficient anti-CD32a antibody is administered prior to, concurrently with, or following the non-anti-CD32a monoclonal antibody.
 13. The method of claim 10, wherein the IgG immune complex-mediated disease or disorder occurs in a patient being treated with a non-anti-CD32a monoclonal antibody for the treatment of rheumatoid arthritis, systemic lupus erythematosus (SLE), lupus nephritis, or inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.
 14. The method of claim 1, wherein the subject has a CD32a-mediated disease or disorder characterized by IgG localized on the surface of cells circulating in the blood of the human subject.
 15. The method of claim 14, wherein the circulating cell type is comprised of one or more of the following: platelets, erythrocytes, monocytes, neutrophils, basophils, eosinophils, B-lymphocytes, macrophages, mast cells, leukemia cells, or microbes.
 16. The method of claim 14, wherein the disease or disorder is selected from one or more of the following: thrombocytopenia, leukopenia, neutropenia, lymphopenia, monocytopenia, anemia, hemolytic anemia, or sepsis.
 17. A method for treating antibody-mediated allergic or hypersensitivity reactions of type I, type II, or type III in a human subject comprising: administering a therapeutically effective amount of an effector-deficient anti-CD32a monoclonal antibody to a human subject, wherein the antibody comprises at least a portion of an Fc region and is effector-deficient, thereby treating the antibody-mediated allergic or hypersensitivity reactions of type I, type II, or type III.
 18. The method of claim 17, wherein the allergic disorder is selected from the group consisting of atopy, contact dermatitis, allergic rhinitis, systemic anaphylaxis, localized anaphylaxis as exhibited in hay fever, asthma, hives, food allergies, and eczema, allergic reactions to vaccines, allergic reactions to foods, allergic reactions to, allergic reactions to insect products, allergic reactions to drugs, allergic reactions to mold spores, allergic reactions to animal hair and dander, allergic reactions to latex, blood transfusion reactions, platelet transfusion reactions, erythrocyte transfusion reactions, erythroblastosis fetalis, hemolytic anemia, serum sickness, infusion reactions, necrotizing vasculitis, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, and allergic reactions to microorganisms.
 19. (canceled)
 20. The method of claim 1, wherein the monoclonal antibody is humanized.
 21. The method of claim 1, wherein the antibody comprises: a. a heavy chain variable region CDR1 sequence comprising a sequence that is identical to the sequence YYWMN (SEQ ID NO: 1) or GFTFSYYW (SEQ ID NO: 73 and SEQ ID NO: 88); b. a heavy chain variable region CDR2 sequence comprising a sequence that is identical to the sequence EIRLKSNNYATHYAESVKG (SEQ ID NO: 2) or IRLKSNNYAT (SEQ ID NO: 74 and SEQ ID NO: 89); c. a heavy chain variable region CDR3 sequence comprising a sequence that is identical to the sequence RDEYYAMDY (SEQ ID NO: 3) or NRRDEYYAMDY (SEQ ID NO: 75 and SEQ ID NO: 90); d. a light chain variable region CDR1 sequence comprising a sequence that is identical to the sequence RASESVDNFGISFMN (SEQ ID NO: 4) or ESVDNFGISF (SEQ ID NO: 76 and SEQ ID NO: 91); e. a light chain variable region CDR2 sequence comprising a sequence that is identical to the sequence GASNQGS (SEQ ID NO: 5) or GAS (SEQ ID NO: 77 and SEQ ID NO: 92); and f. a light chain variable region CDR3 sequence comprising a sequence that is identical to the sequence QQSKEVPWT (SEQ ID NO: 6) or QQSKEVPWT (SEQ ID NO:78 and SEQ ID NO: 93).
 22. The method of claim 21, wherein the antibody comprises a variable heavy chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 8 or SEQ ID NO: 12, and a variable light chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 10 or SEQ ID NO:
 14. 23. The method of claim 21, wherein the antibody comprises: a. a heavy chain sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 16, SEQ ID NO: 18, or SEQ ID NO: 20; and b. a light chain sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 22, or SEQ ID NO:
 24. 24. The method of claim 1, wherein the antibody comprises: a. a heavy chain variable region CDR1 sequence comprising a sequence that is identical to the sequence NYGMN (SEQ ID NO: 25) or GYTFTNYG (SEQ ID NO: 79); b. a heavy chain variable region CDR2 sequence comprising a sequence that identical to the sequence WLNTYTGESIYPDDFKG (SEQ ID NO: 26) or LNTYTGES (SEQ ID NO: 80); c. a heavy chain variable region CDR3 sequence comprising a sequence that is identical to the sequence GDYGYDDPLDY (SEQ ID NO: 27) or ARGDYGYDDPLDY (SEQ ID NO: 81); d. a light chain variable region CDR1 sequence comprising a sequence that is identical to the sequence RSSKSLLHTNGNTYLH (SEQ ID NO: 28) or KSLLHTNGNTY (SEQ ID NO: 82 and SEQ ID NO: 100); e. a light chain variable region CDR2 sequence comprising a sequence identical to the sequence RMSVLAS (SEQ ID NO: 29) or RMS (SEQ ID NO: 83 SEQ ID NO: 101); and a light chain variable region CDR3 sequence comprising a sequence that is identical to the sequence MQHLEYPLT (SEQ ID NO: 30 and SEQ ID NO: 84 and SEQ ID NO: 102).
 25. The method of claim 24, wherein the antibody comprises: a. a variable heavy chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 32, SEQ ID NO: 36, or SEQ ID NO: 38; and b. a variable light chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 34, SEQ ID NO: 41 or SEQ ID
 85. 26. The method of claim 24, wherein the antibody comprises: a. a heavy chain sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, or SEQ ID NO: 49; and b. a light chain sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 51, SEQ ID NO: 53 or SEQ ID NO:
 87. 27. The method of claim 1, wherein the antibody comprises: a. a heavy chain variable region CDR1 sequence comprising a sequence that is identical to the sequence SYGMH (SEQ ID NO: 54) or GFTFSSYG (SEQ ID NO: 94); b. a heavy chain variable region CDR2 sequence comprising a sequence that is identical to the sequence VIWYDGSNYYYTDSVKG (SEQ ID NO: 55) or IWYDGSNY (SEQ ID NO: 95); c. a heavy chain variable region CDR3 sequence comprising a sequence that is identical to the sequence DLGAAASDY (SEQ ID NO: 56) or ARDLGAAASDY (SEQ ID NO: 96); d. a light chain variable region CDR1 sequence comprising a sequence that is identical to the sequence RASQGINSALA (SEQ ID NO: 57) or QGINSA (SEQ ID NO: 97); e. a light chain variable region CDR2 sequence comprising a sequence that is identical to the sequence DASSLES (SEQ ID NO: 58) or DAS (SEQ ID NO: 98); and f. a light chain variable region CDR3 sequence comprising a sequence that is identical to the sequence QQFNSYPHT (SEQ ID NO: 59) or QQFNSYPHT (SEQ ID NO: 99).
 28. The method of claim 27, wherein the antibody comprises: a. a variable heavy chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 61; and b. a variable light chain sequence comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO:
 63. 29. The method of claim 27, wherein the antibody comprises: a. a heavy chain sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 65 or SEQ ID NO: 67; and b. a light chain sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO:
 69. 30. (canceled) 